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CONCOMITANT TARGETING OF THE MTOR/MAPK PATHWAYS: NOVEL 
THERAPEUTIC STRATEGY IN SUBSETS OF NON-SMALL CELL LUNG CANCER 
 
Dennis Ruder, B.S. 
Advisory Professor: Ignacio I. Wistuba, M.D. 
 
Over the last decade, a paradigm-shift in lung cancer therapy has evolved into 
targeted-driven medicinal approaches. However, patients frequently relapse and 
develop resistance to available therapies. Herein, we utilized genomic mutation data 
from advanced chemorefractory non-small cell lung cancer (NSCLC) patients enrolled 
in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer 
Elimination (BATTLE-2) clinical trial to characterize novel actionable genomic 
alterations potentially of clinical relevance. We identified RICTOR alterations 
(mutations, amplifications) in 17% of lung adenocarcinomas and found RICTOR 
expression correlates to worse overall survival. There was enrichment of MAPK 
pathway genetic aberrations in key oncogenes (e.g. KRAS, BRAF, NF1) associated 
with RICTOR altered cases, underscoring that RICTOR could serve as an important 
co-oncogenic driver in specific molecular settings. Moreover, we utilized a panel of 
RICTOR amplified NSCLC cell lines and found that RICTOR genetic blockade 
impaired malignant properties seen by reduced effects on cell survival and 
tumorigenicity potential. We uncovered a compensatory activation of the MAPK 
signaling pathway following RICTOR knockdown specifically in KRAS co-mutational 
settings, exposing a unique therapeutic vulnerability. Our in vitro and in vivo data 
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testing concomitant pharmacologic inhibition of both pathways (PI3K/AKT/mTOR and 
MAPK) via AZD2014 (mTORC1/2 inhibitor) and selumetinib (MEK1/2) resulted in 
synergistic responses of antitumor effects. Given the large population of patients 
affected by NSCLC, our study provides a treatment rationale for a specific subset of 
patients who may benefit from genomic stratification based on RICTOR/KRAS 
alterations, further underscoring the need for proper patient selection to gain optimal 
therapeutic response. 
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Chapter 1 
Introduction 
1.1 Lung Cancer Overview 
Lung cancer continues to affect the lives of more than 1.6 million new patients   
annually and remains a major global health problem. It is estimated to affect more 
than 224,000 people and lead to over 159,000 new deaths in the US each year (1). 
Despite advancements in detection methods and standard of care, over a third of 
patients that are diagnosed with lung cancer present at late stage with metastatic 
disease, resulting in a dismal 5-year survival rate of less than 5% which has remained 
stagnant over the past few decades (2). What was once considered a single disease 
entity, lung tumors exist as diverse subtypes with unique pathologies. The two major 
forms of lung cancer are non-small cell lung cancer (NSCLC) (accounts for 
approximately 85% of all lung tumors) and small-cell lung cancer (SCLC) (about 
15%). Specifically, NSCLC can be further subdivided into three major histotypes: lung 
adenocarcinoma (50%), squamous-cell carcinoma (30%), and large-cell lung cancer 
(15%) (Figure 1) (3).   
1.2 Paradigm Shift in Therapy and Molecular Characterization of NSCLC 
It is well recognized that heterogeneity amongst the molecular architecture of 
tumors is responsible for diverse clinical outcomes and responses even in patients 
with similar clinical staging and histologic characteristics. This is due to our increased 
understanding that NSCLC is a disease comprised of diverse clinical, histological, and 
genetically distinct subtypes.  
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Figure 1. Non-small cell lung cancer (NSCLC) frequency based on histology. 
 
With significant advancements in genomic sequencing technologies, treatment 
strategies and management of NSCLC, particularly in lung adenocarcinomas, are 
heavily based on screening tumors for an array of biomarkers that are of predicative 
and/or prognostic value to help oncologists assign patients that would be most 
sensitive to specific targeted therapies (4). A multitude of oncogenic driver mutations 
that feed into key signaling pathways have now been elucidated that lead to 
tumorigenesis and tumor progression (Figure 2) (5). Specifically, significant effort in 
the last decade had centered upon developing targeted agents against mutations of 
the epidermal growth factor receptor (EGFR, ~17% mutations) and in anaplastic 
lymphoma kinase (ALK) fusions/rearrangements (~7%), with much success attributed 
to examples such as EGFR tyrosine kinase inhibitors (TKIs) and crizotinib, 
respectively. In both subgroups, the response rates in patients properly stratified to 
Adenocarcinoma
50%
Squamous Cell
30%
Large 
Cell
15%
Other
5%
NSCLC by histology
3 
 
these targeting agents were as high as 70% in crucial phase 3 clinical trials (6, 7). 
Identification of such driver mutations and the responses seen in patients 
appropriately stratified serve as classic examples for the impetus of rational design of 
new and improved targeted agents that hit other key oncogenes in NSCLC. Such 
alterations are often found in receptors or protein kinases and can activate a complex 
cascade of oncogenic signaling paths such as the mitogen-activated protein kinase 
(MAPK) cascade and the phosphoinositide 3-kinase (PI3K)-PKB (AKT) pathway. The 
frequency of other genomic alterations that occur in lung adenocarcinomas include 
KRAS (25%), NF1 (8.3%), MET (3%), ROS1 (2%), BRAF (2%), RET (2%), and others 
(Figure 2) (5, 8). Ultimately, these mutant onco-drivers stimulate such pathways that 
lead to uncontrolled cancer cell growth, proliferation and pro-survival transcriptional 
reprogramming (9-12). However, approximately 25-30% of lung adenocarcinomas do 
not have known, targetable mutations, and therefore these patients are treated with 
standard cytotoxic chemotherapies with limited success. Moreover, although targeted 
therapies against discovered alterations lead to remarkable initial responses, the 
inevitable emergence of drug resistance still occurs and patients ultimately relapse. 
Mechanisms of resistance can occur either through the acquisition of secondary 
mutations in the targeted kinase that can potentially negate the drug binding affinity, 
or by compensating via alternate bypass signaling mechanisms, though other 
resistance mechanisms are possible (13, 14). Therefore, it is imperative to take into 
account the molecular underpinnings of each patient’s tumor and utilize a 
personalized medicine approach to identify novel actionable targets and therapeutic 
strategies tailored to that individual.   
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Figure 2. Frequency of molecular aberrations in various driver oncogenes in 
lung adenocarcinomas and current available drugs against these oncogenic 
proteins. These frequencies are a combination of data from the Lung Cancer 
Mutation Consortium and frequencies listed in Shea et al. (15). Shown in the boxes 
are the available drugs in addition to their developmental phase. EGFR, epidermal 
growth factor receptor; ALK, anaplastic lymphoma receptor tyrosine kinase; MET, 
mesenchymal-to-epithelial transition factor; HER2, erb-b2 receptor tyrosine kinase 2; 
ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; BRAF, B-Raf proto-
oncogene, serine/threonine kinase; RET, ret proto-oncogene; NTRK1, neurotrophic 
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tyrosine kinase receptor type 1; PIK3A, phosphatidylinositol-4,5-bisphosphate 3-
kinase catalytic subunit alpha; MEK1, mitogen-activate protein kinase kinase 1; 
KRAS, Kirsten rat sarcoma viral oncogene homolog. 
Reprinted with permission from: Tsao AS et al. Scientific Advances in Lung Cancer 
2015. J Thorac Oncol. 2016;11(5):613-38. (5) License # 3957960028670 
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1.3 The PI3K/AKT/mTOR signaling pathway 
The phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB/AKT)-
mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) pathway is one of the 
most frequently deregulated signaling pathways in cancer and heavily enhances 
tumorigenic potential with its regulatory processes involving cellular growth, 
proliferation, survival, migration/invasion, and angiogenesis (16-18) (Figure 3). Under 
physiological condition, this intricate pathway is stimulated via ligand activation of 
receptor tyrosine kinases (RTKs) such as EGFR, ErbB3 IGF1-R, resulting in 
phosphorylation of tyrosine residues on the intracellular portion of the receptors (16, 
19). This results in the direct recruitment of PI3K to the membrane of the cell where 
conversion of the second messenger phosphatidylinositol-4,5-bisphosphate (PIP2) to 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) can occur (20). PIP3 is then able to 
recruit 3-phosphoinositide dependent protein kinase-1 (PDK1) and the 
serine/threonine kinase AKT, via their pleckstrin homology (PH) domains, to the 
plasma membrane. PDK1 then phosphorylates AKT on Thr308 in the catalytic domain 
and the mammalian target of rapamycin complex 2 (mTORC2) serves to fully activate 
AKT on Ser473 in the hydrophobic motif (21). Active AKT mediates numerous cellular 
processes including survival, proliferation, apoptosis, migration and invasion via 
regulation of downstream effectors spanning multiple pathways (22-27). Typically, 
AKT can then lead to phosphorylation and inactivation of the GTPase-activating 
proteins (GAPs) tuberous sclerosis 1 and 2 (TSC1/TSC2), resulting in the 
accumulation of GTP-bound Ras homologue enriched in brain (RHEB) ultimately 
leading to activation of mammalian target of rapamycin complex 1 (mTORC1). Once 
activated, mTORC1 can directly regulate cellular processes involved in metabolism 
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and biosynthesis. Specifically, mTORC1 phosphorylates p70 S6 kinase and the 
translation repressor 4E-binding protein 1 (4EBP1). Phosphorylation of 4EBP1 inhibits 
the binding ability to eIF4E and initiates cap-dependent translation (28, 29). Similarly, 
S6K activation aids in the cap-dependent translation mechanism and also promotes 
S6 ribosomal protein (S6RP) phosphorylation. Collectively, this pathway converges on 
important cellular mechanisms resulting in increased protein translation, ribosome 
biogenesis and inhibition of autophagy (30-32).  
Moreover, key components of the mTOR pathway are the two structurally and 
functionally distinct mTOR complexes. The essential mTORC1 subunits are the 
Ser/Thr kinase mTOR, the regulatory-associated protein of mTOR (RAPTOR) which 
serves as a scaffolding unit, mammalian lethal with Sec13 protein 8 (mLST8), proline-
rich AKT substrate 40 kDa (PRAS40), and DEP-domain-containing mTOR-interacting 
protein (DEPTOR) (33, 34). The functional and regulatory mechanisms of mTORC1 
have been characterized extensively since the discovery of rapamycin, an antifungal 
metabolite produced from the bacterium Streptomyces hygroscopicus, which inhibits 
mTOR and was later discovered to exhibit anti-proliferative and immunosuppressive 
effects (35). mTORC1 activity can be modulated by amino acid availability, nutrient 
levels, cellular energy status, and growth factors and ultimately coordinates regulatory 
signaling for translation and ribosome biogenesis (as described above). Moreover, 
mTORC1 is directly linked to the regulation of autophagy, and this link has been 
extensively studied due to important implications to cancer biology and treatment (36, 
37). The process of autophagy can be either pro-oncogenic, acting as a survival 
mechanism to aid in growth advantage during stressful cellular conditions, or tumor 
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suppressive in function by preventing the buildup of damaged molecules such as 
organelles and proteins (37-40).  
mTOR can function as part of a second complex, mTORC2, which contains 
some overlapping and distinct protein subunits, namely rapamycin-insensitive 
companion of mTOR (RICTOR), mammalian stress-activated protein kinase 
interacting protein (mSIN1), protein observed with Rictor-1 (PROTOR-1), DEPTOR, 
and mLST8 (36). Relative to mTORC1, the biology of regulation and functionality of 
mTORC2 is still in its infancy, although there is increased appreciation of the 
importance of this complex. Further, although it is established that activation of 
mTORC2 can be mediated by growth factors and PI3K signaling, the precise 
mechanism is poorly understood. One of the major roles elucidated for mTORC2 is 
the phosphorylation and full activation of AKT on Ser473 (21, 41).  It can also 
phosphorylate and activate several other protein A/G/C (AGC) kinase family members 
such as serum glucocorticoid-induced kinase (SGK) and protein kinase C (PKC) 
isoforms, regulating cytoskeletal reorganization, cell survival, and lipid metabolism 
(41-43). 
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Figure 3. The mTOR signaling pathway. Red lines indicate the different 
mechanisms of mTOR activation. Abbreviations: AMPK, AMP-activated kinase; 
deptor, DEP-domain-containing mTOR interacting protein; 4E-BP1, eIF4E-binding 
protein 1; eIF, eukaryotic initiation factors; ERK1/2, extra-cellular regulated kinase 1/2; 
FKBP12, FK506 binding protein 12; IRS, Insulin receptor substrates; mLST8, 
mammalian lethal with Sec13 protein 8; mTORC, mammalian target of rapamycin 
complex; NDRG1, N-Myc downstream regulated gene-1; PDK1, phosphoinositide-
dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 
bisphosphate; PIP3, phosphatidylinositol triphosphate; PRAS40, proline-rich Akt1 
substrate 1; protor, protein observed with Rictor-1/Proline rich Akt substrate of 40kDa; 
P70S6K1, p70 S6 kinase 1; Rheb, Ras homolog enriched in brain; mSin1, stress 
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activated protein kinase interaction protein 1; SGK, serum and glucocorticoid protein 
kinase; TSC, tuberous sclerosis complex; TKR, tyrosine kinase receptor.  
Reprinted with permission from: Chapuis N. et al. Perspectives on inhibiting mTOR as 
a future treatment strategy for hematological malignancies. Leukemia. 2010;24 
(10):1686-99 (44). License # 3960460046414 
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1.4 The RAS/RAF/MEK/ERK (MAPK) signaling pathway 
The mitogen-activated protein kinase (MAPK) signaling pathway is a highly 
conserved family of kinases and is deregulated in about one-third of all human 
cancers (45).  An overview of this signaling pathway is illustrated in Figure 4 (46). This 
pathway is primarily induced by cell surface receptors such as RTKs. Dimerization of 
these receptors following ligand binding activates the receptors and 
autophosphorylation of tyrosine residues occurs in the intracellular domain. 
Phosphorylation of these residues acts as docking sites for various proteins 
containing Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains (e.g. 
Grb2, growth factor receptor-bound protein 2). Grb2, serving as an adaptor molecule, 
can then recruit son of sevenless (SOS), a GTPase exchange factor (RasGEF), to 
localize to the cell membrane. Inactive Ras-GDP is largely associated with the plasma 
membrane, but following activation and catalytic transformation to Ras-GTP by SOS, 
RAS is able to recruit the RAF family of kinases (A-RAF, B-RAF, C-RAF) to the 
membrane and activate them. Subsequent activation loop phosphorylations occur in 
which RAF activates downstream MEK1/2, and MEK1/2 ultimately activates ERK1/2 
at threonine and tyrosine residues, leading to a cascade of reactions regulating cell 
survival, proliferation, and motility. The main downstream targets elucidated of 
MEK1/2 are ERK1/2, while ERK1/2 has numerous downstream effectors (47). 
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Figure 4. The RAS-RAF-MEK-ERK signaling pathway. The classical MAPK 
pathway is activated in human tumors by several mechanisms including the binding of 
ligand to receptor tyrosine kinases (RTK), mutational activation of an RTK, by loss of 
the tumor suppressor NF1, or by mutations in RAS, BRAF, and MEK1. 
Phosphorylation and thus activation of ERK regulates transcription of target genes 
that promote cell cycle progression and tumor survival. The ERK pathway contains a 
classical feedback loop in which the expression of feedback elements such as SPRY 
and DUSP family proteins are regulated by the level of ERK activity. Loss of 
expression of SPRY and DUSP family members due to promoter methylation or 
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deletion is thus permissive for persistently elevated pathway output. In the case of 
tumors with V600EBRAF expression, pathway output is enhanced by impaired 
upstream feedback regulation.  
Reprinted with permission from: Pratilas CA, Solit DB. Targeting the mitogen-
activated protein kinase pathway: physiological feedback and drug response. Clinical 
cancer research: an official journal of the American Association for Cancer Research. 
2010;16(13):3329-34. (46) License # 3960600731382 
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1.5 Cross-talk between PI3K/mTOR and MAPK Pathways 
Traditional views of major signaling networks such as the PI3K/AKT/mTOR and 
RAS/RAF/MEK/ERK (MAPK) pathways arrange these mechanisms as linear and 
independent pathways that determine cellular fate. However, numerous reports to 
date have described that these parallel pathways are very intricate and in fact there 
are multiple nodes of cross-talk, resulting in cross-activation, inhibition, and 
convergence of pathways on effector targets (48, 49). This is evidenced by reports 
suggesting that approximately 802 active proteins exist that are involved in PI3K-
mediated signaling and over 2,000 connections exist that relate to the MAPK pathway 
family kinases (50, 51). Thus, the opportunity for cross-regulatory mechanisms 
amongst these interactomes to occur is not surprising and both of these major 
oncogenic pathways affect each other at various phases of signal transduction, 
depending on the cellular context and need. A summary of major cross-talk 
mechanisms that have been reported are highlighted in Figure 5 (49). 
In both pathways, there are various kinases that have limited specificity of 
known substrates (e.g. mTORC1, RAF, MEK) and others that activate various 
members of their respective pathways on top of a multitude of other effector targets 
(e.g. S6K, ERK, AKT, RSK) (49). The integration of the PI3K/mTOR and MAPK 
pathways therefore mostly occurs through the latter kinases noted. Cross-inhibition of 
these pathways has been elucidated following studies utilizing chemical methods of 
blockade, wherein one pathway is blocked inducing a release mechanism of the basal 
cross-inhibitory effects leading to activation of the alternate pathway. For instance, 
inhibitors of MEK have been shown to increase epidermal growth factor (EGF)-
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mediated activation of AKT through the recruitment of PI3K to the EGFR receptor (52, 
53).  
Moreover, a cross-inhibitory mechanism between RAF and AKT has been 
proposed that is induced by levels of IGF1 stimulation (54). Studies reported that the 
negative regulations of downstream ERK signaling by AKT occur through AKT’s 
inhibition on phosphorylation sites in the upstream RAF N-terminus domain, 
specifically on the Ser364/259 residues (55-57). These conserved sites are 
recognized by 14-3-3 dimers which can immobilize the auto-inhibited RAF in the 
cytosolic region away from its upstream and downstream effectors RAS and MEK, 
respectively (58).  
Cross-activation can also occur between both pathways. The MAPK pathway 
can activate the PI3K/mTOR pathway through direct regulation of PI3K, mTORC1, 
and TSC2. Activated RAS, when bound to GTP, can allosterically activate PI3K 
through direct binding (59-61). Moreover, constitutive activation from a mutant RAS, 
EGF stimulation, or phorbol esters can lead to hyperactive MAPK signaling, resulting 
in ERK and its effector ribosomal s6 kinase (RSK) to stimulate mTORC1 activity by 
inhibiting the GTPase-activating protein (GAP) function of the TSC1/2 complex (62). 
Additionally, pathway convergence can occur via multiple mechanisms signaled by 
S6K, AKT, ERK, and RSK since these key proteins share similar substrates and 
sometimes activate the same target simultaneously to fulfill specific processes such 
as cell survival, proliferation, motility and metabolism. Prime examples include the 
regulation of the forkhead box O (FOXO) and glycogen synthase kinase 3 (GSK3) 
(49). The FOXO family of proteins control expression of molecules involved in the 
apoptotic cascade and key cell cycle regulators, with the primary role of inhibiting cell 
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survival and proliferation. ERK, AKT, and SGK can all phosphorylate various 
members of the FOXO proteins on specific residues that lead to their ultimate 
degradation and sequestration, therefore restricting their nuclear translocation and 
preventing apoptotic transcriptional machinery (63-66). Moreover, GSK3 can be 
directly regulated by ERK, AKT, PKC, and S6K. GSK3 functions to inhibit survival, 
proliferation, and motility targets including beta-catenin and various adhesion proteins. 
It can also phosphorylate and activate TSC2 and lead to inactivation of mTORC1 
signaling (67).  
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Figure 5. Pathway Crosstalk. The Ras-MAPK and PI3K-mTORC1 pathways 
regulate each other via cross-inhibition (red) and cross-activation (green). Each 
pathway has a mechanism to negatively feed onto the other: ERK phosphorylation of 
GAB and AKT phosphorylation of Raf. Components of the Ras-ERK pathway (Ras, 
Raf, ERK, and RSK) also positively regulate the PI3K-mTORC1 pathway. TSC2 and 
mTORC1 are key integration points that receive many inputs from both the Ras-ERK 
and PI3K signaling. Positive regulation of the substrate protein is shown as an arrow. 
Negative regulation of the substrate protein is depicted as a blunt-ended line. 
Reprinted with permission from: Mendoza MC, Er EE, Blenis J. The Ras-ERK and 
PI3K-mTOR pathways: cross-talk and compensation. Trends in biochemical sciences. 
2011;36(6):320-8. doi: 10.1016/j.tibs.2011.03.006. (49) License # 3961020803450 
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1.6 Therapeutic implications of targeting the PI3K/AKT/mTOR pathway 
NSCLC harbors molecular alterations involving the PI3K/AKT/mTOR and 
MAPK pathways, and thus, pharmacologic inhibitors of both pathways are given 
extensive priority for development to further test in the clinic. Deregulations of the 
PI3K/AKT/mTOR pathway occur at variable frequencies in lung tumorigenesis and 
have been correlated with more advanced stage disease as well as tumor grade (68). 
Aberrant mechanisms of activation can occur through a variety of ways, including 
upregulation of RTK activity upstream of PI3K, amplification and/or mutations in 
PIK3CA, KRAS, STK11, AKT, or inactivating mutations in the negative regulator 
phosphatase and tensin homolog (PTEN) (69). Collectively, targeting these pathways 
remains both an opportunity and a challenge for cancer treatment. 
The earliest mTOR inhibitor discovered was rapamycin and was initially 
developed for use as an active anti-fungal and immunosuppressive agent. The anti-
proliferative effects first seen in studies involving cancer cell lines led to the active 
interest in the mTOR pathway as a potential anti-cancer target of interest. The 
mechanism by which rapamycin exerts its effects is by allosteric inhibition of the 
mTORC1 complex with high affinity to the FKBP-12/rapamycin binding (FRB) domain 
of mTOR (70). Additionally, rapamycin has been shown to selectively inhibit mTORC1 
activity and have minimal effects against mTORC2; although extended treatments 
have shown to increase sensitivity of this complex to the drug in some cellular 
contexts (71). The general effects seen in the clinic with rapamycin have been modest 
and mainly result in stability of disease. Analogs of rapamycin have since been 
developed, which have similar molecular structures but differing physiochemical 
properties. Examples of these rapalogs include everolimus, temsirolimus, and 
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deforolimus, and have undergone numerous clinical trials in a wide range of cancers. 
Thus far, everolimus and temsirolimus have been approved for advanced renal cell 
carcinoma (72, 73). To increase the anti-tumor response, numerous strategies have 
been proposed including the combinations of rapalogs with chemotherapeutic drugs 
to induce cell death or combining targeted therapies specific for the PI3K/AKT/mTOR 
pathway or parallel pathways.  
Moreover, one of the major limitations in the effectiveness of rapalogs has 
been the discovery of de-repression of negative feedback loops mediated by 
mTORC1. Studies have elucidated that mTORC1 inhibition releases a negative 
feedback loop on the insulin receptor substrate (IRS-1) and growth-factor-receptor-
bound protein 10 (GRB10), resulting in increased RTK signaling to PI3K, AKT, and/or 
to other pathways through ERK1/2. Also, rapalogs have been shown to shut down 
downstream S6K signaling completely, but only inhibit the translational repressor 
4EBP1 transiently, therefore protein synthesis, cell proliferation and survival 
mechanisms can still continue to occur (69, 74, 75). The increased understanding of 
the drawbacks of first generation mTOR inhibitors resulted in the advent of new 
catalytic ATP-competitive inhibitors being developed targeting the mTOR kinase 
domain, with the expectation to inhibit both of the critical mTORC1 and mTORC2 
complexes and prevent feedback activation of AKT (76, 77). Early clinical trials 
identified mTORC1/2 inhibitors having superior single agent activity compared with 
previous rapalogs. Partial responses have been reported in NSCLC, estrogen 
receptor (ER) positive breast cancer, and hepatocellular carcinoma using either of two 
mTORC1/2 inhibitors (AZD2014 and CC-223); however, optimized patient selection is 
20 
 
still further warranted and these drugs have not yet reached the initial expectations as 
single agents (78, 79). 
The critical role of PI3K in cancer led to significant efforts in developing drugs 
targeting it, many of which are still undergoing clinical evaluation in various phases of 
trials. There are three distinct PI3K classes which are further subdivided into varying 
isoforms. Class IA PI3Ks are the most studied and are made up of a p110 catalytic 
subunit (encoded by three homologous isoforms: p110α, p110β and p110δ) and a 
p85 regulatory subunit (16). Compared to other targeted drugs aimed at oncogenic 
kinases (e.g. EGFR, RAF, ALK), inhibitors against PI3K have had limited efficacy as 
single arm treatments in early phase clinical trials in tumors that harbored PI3K 
pathway hyperactivation (18). First generation pan-PI3K inhibitors were initially 
developed, such as wortmannin and LY294002, but were hindered in early phases of 
human trials due to their toxicities and lack of specificity. Most of these inhibitors in 
early clinical trials are catalytic ATP-competitive inhibitors and target all class I PI3K 
isoforms with similar effectiveness. This could be problematic in that these drugs 
target all the class I PI3K isoforms regardless of their actual oncogenic role, and 
moreover, have been shown to display off-target effects on other effectors of the 
phosphatidylinositol 3-kinase-related kinases (PIKK) family, including ATM 
Serine/Threonine Kinase (ATM), Ataxia Telangiectasia And Rad3-Related Protein 
(ATR), and DNA-dependent Protein Kinase (DNA-PK) (80, 81). Therefore, isoform-
specific inhibitors are now being developed for clinical testing with the expectation for 
achieving better safety and efficacy profiles and reduce toxicity. Determining the 
specific disease settings by which the different PI3K isoforms contribute to the 
tumorigenic phenotype will be crucial to increase the effectiveness of these inhibitors.  
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Furthermore, AKT inhibitors have also been developed, particularly since this 
master regulator integrates the central node of the PI3K/mTOR pathway. Several ATP 
mimetics and inhibitors of non-catalytic sites of AKT have been pushed into the clinic 
for evaluation. Although AKT1 activating mutations occur infrequently in NSCLC, 
overexpression of AKT1 and AKT2 occurs at higher rates, exposing possible 
therapeutic vulnerability to these AKT inhibitory agents (69, 82). However, early phase 
trials have shown, at best, stability in disease as the most encouraging overall 
response with anti-proliferative, rather than anti-tumorigenic, effects mediated by 
single agent therapy (83, 84).  Furthermore, experimental models and early clinical 
trials have suggested that AKT-specific inhibitors may be most efficacious in specific 
molecular settings, particularly in tumors harboring PTEN loss or PIK3CA mutations, 
leading to the hyperactivity of the AKT mediated pathway. Importantly, resistance 
mechanisms such as the relief of mTORC1 feedback inhibition on IRS-1 signaling  
(mentioned above), and de-repression of FOXO leading to increased activation of 
RTKs, PI3K, PDK1, and other targets downstream of AKT, have been also elucidated 
(85). In all, AKT inhibitors are being approached with caution as their disturbance to 
the AKT pathway can lead to metabolic dysregulations and hyperglycemia (86).  
1.7 Therapeutic implications of targeting the RAS/RAF/MEK (MAPK) pathway 
Three RAS genes (HRAS, NRAS, KRAS) have been identified and aberrant 
mutations in these isoforms have been discovered to have major oncogenic 
implications. Specifically, KRAS mutations are the most prevalent and have been 
found in 1/3 of all cancers, including colon, pancreatic, and lung. The most frequent 
codons of KRAS that are mutated in lung cancers occur at codons 12, 13 and 61 (87). 
Mutations in this oncogene result in a constitutively active KRAS leading to 
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hyperactivity of the MAPK and mTOR pathways. For over two decades, numerous 
strategies were attempted to target oncogenic KRAS signaling, including direct 
inhibitors of the protein, RNA interference, inhibitors that prevent localization of RAS 
to the membrane, and targeting drugs of downstream effectors (88). One of the 
earliest efforts to block RAS was through abrogation of its localization via 
farnesylation to the plasma membrane via farnesyl transferase inhibitors. However, 
this drug class failed when pursued for evaluation in pre-defined mutant KRAS 
cancers, since eventual recognition that KRAS could be alternatively modified via 
other mechanisms to relieve the translocation repression, ultimately allowed KRAS 
back to the plasma membrane even in the absence of farnesylation (89).  
Refocused therapeutic strategies have gained momentum over the years by 
developing targeted therapies against effectors downstream of KRAS. Notably, the 
identification of BRAF mutations in melanomas have sparked clinical testing of 
multiple RAF kinase inhibitors. BRAF mutations have been reported in about 2-3% of 
lung adenocarcinomas. Based on previous marked anti-tumor activity in BRAFV600E 
mutant melanoma, mutant BRAF inhibitors (e.g. dabrafenib, vemurafenib) have made 
it into clinical evaluation for advanced stage BRAF positive NSCLC (90). However, the 
efficacy of these inhibitors in the KRAS mutant setting still remains to be resolved as 
responses with single agent RAF inhibitors have been poor, specifically in KRAS 
mutant settings. Studies have elucidated paradoxical reactivation of downstream 
ERK1/2 following BRAF inhibition. Specifically, BRAF inhibitors resulted in either relief 
of RAF-inhibitory autophosphorylation mechanisms or RAF inhibitor-induced 
transactivation of RAF dimerization, leading to increased ERK signaling (91-94). 
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Thus, combination regimens to combat such bypass mechanisms of resistance are 
still being established and evaluated in the clinical setting.  
Resistance mechanisms of RAF inhibition prompted avid development of 
downstream MEK targeted therapies with the hopes of more durable pathway 
inhibition. Selumetinib and trametinib are two allosteric MEK1/2 inhibitors that have 
been evaluated as either single agents or in combination with cytotoxic agents to 
target mutant KRAS NSCLC. Early stage clinical trials showed that selumetinib as a 
single agent led to tumor responses in advanced cancer patients; however, phase II 
trials in selected patient populations with previously treated NSCLC (including some 
patients with KRAS mutations) showed little clinical activity (95, 96). Further, based on 
pre-clinical in vivo evidence, studies showed that cytotoxic agents such as docetaxel 
in combination with selumetinib resulted in synergistic anti-tumor effects, and thus 
sparked clinical trials of this dual combination. Results from a phase II trial evaluating 
this combination in advanced stage (III-IV) chemo-refractory KRAS mutant NSCLC 
patients found a trend in better overall survival (OS), but the study failed to meet the 
primary endpoint, and only a fraction of the patients were partial responders (97). In 
addition, trametinib has also been examined in the clinic. A phase II trial evaluating 
trametinib as monotherapy versus docetaxel in KRAS mutant NSCLC resulted in no 
statistically significant or clinically meaningful endpoints (98). Current studies are 
evaluating the combination of trametinib with chemotherapy drugs such as docetaxel 
or pemetrexed. Collectively, it can be concluded that although MEK inhibitors can 
have the potential for significant anti-tumor effects, better patient selection, 
optimization of dosing regimens, and rational combinatorial therapeutic strategies are 
necessary to find significant clinical utility of these agents. 
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1.8 RICTOR’s mTORC2-dependent and independent tumorigenic functions 
The mTORC2 complex is comprised of mTOR and the essential components 
RICTOR, mSIN1, and mLST8. This complex regulates a variety of important cellular 
functions including proliferation, survival, and metabolism through phosphorylation of 
various AGC kinase family members such as AKT, PKCα, and SGK (99). RICTOR 
and mSIN1 function as adaptor molecules serving as critical regulators of mTORC2 
substrate specificity and binding. Specifically, RICTOR’s Gly-934 residue is critical in 
the formation of the RICTOR/mSIN1 heterodimer interaction required for the structural 
integrity, stability, and functionality of the complex (100).  
Increasing reports have elucidated the contribution of RICTOR toward 
tumorigenic phenotypes functioning through mTORC2-dependent and independent 
manners. Initially, RICTOR’s ortholog studied in Dictyostelium was found to be a 
mediator of cell migration and chemotaxis (101). Moreover, multiple in vitro studies 
have indicated RICTOR’s role, in conjunction with mTORC2, in cell migration and 
cytoskeletal regulation via the phosphorylation of PKCα, paxillin, RhoaA, and Rac1 
(41, 102). Moreover, mTORC2 activity is elevated in gliomas, as evidenced by 
overexpression of RICTOR in cell lines and primary tumor cells, resulting in enhanced 
growth and cellular motility (103). Although most of the functional roles of RICTOR 
have been characterized as part of mTORC2, RICTOR carries exclusive independent 
roles. For example, RICTOR was shown to form a separate complex with Myo1c, 
independent of mTORC2, and participates in cortical actin remodeling events (104). 
Recently, insight into the mechanism underlying RICTOR’s regulation of cell migration 
and potential contribution to metastasis was elucidated by finding that RICTOR 
suppresses RhoGDI2, independently of the mTORC1/2 complexes, promoting the 
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activity of the Rho proteins RAC1 and CDC42 (105, 106). Importantly, RhoGDI2 has 
been previously implicated as an invasion and metastasis suppressor gene and thus, 
its loss has been associated with metastatic cancers (107). 
 Additionally, RICTOR can interact with integrin-linked kinase (ILK) to increase 
AKT phosphorylation and regulate cancer cell survival, and this RICTOR/ILK complex 
is also a critical component and mediator of TGFβ-1-induced epithelial-to-
mesenchymal transition (EMT) in mammary epithelial cells (108, 109). Further, a 
kinase-independent function for RICTOR has been proposed through its specific 
association with CULLIN-1 and RBX1, forming a functional E3 ubiquitin ligase 
complex that promotes SGK1 ubiquitination and degradation, providing a mechanistic 
explanation for the high SGK1 expression in various cancers (110, 111). Micro-RNA 
(miRNA) regulation of RICTOR has also been reported by linking the overexpression 
of RICTOR as a target of miR-218, suggesting that the epigenetic silencing of this 
miRNA and subsequent activation of the AKT signaling pathway significantly 
contributes to oral carcinogenesis (112). Lastly, RICTOR has been shown to be 
required for the development of prostate cancer in the context of PTEN loss, and the 
targeting of RICTOR can induce G1 cell cycle arrest and reduction in cyclin D1 
expression levels in colon, breast, and prostate cancer cells (113-115). In summary, 
RICTOR’s oncogenic role is increasingly becoming evident, as this scaffold molecule 
can regulate a multitude of tumorigenic events such as cellular motility, morphology, 
cell proliferation, survival, and protein degradation. 
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1.9 Hypothesis and specific aims 
In summary, the paradigm shift of treatment and diagnosis of lung cancer has 
emerged from a single disease entity with limited therapeutic opportunity to one that is 
comprised of multiple histotypes, each with its own genomic profile, sparking a 
personalized medicinal approach to therapy. Although there are specific examples of 
targeted therapies making drastic impact on overall survival of patients with tumors 
that are driven by specific oncogenes (e.g. EGFR, ALK, B-RAF), over 30% of lung 
adenocarcinomas are still yet to uncover the genetic underpinnings driving these 
tumors (Figure 2). In an effort to identify novel potentially actionable targets that 
contribute to mechanisms of resistance to targeted therapies, we utilized molecular 
profiling data associated with the BATTLE-2 clinical trial, which enrolled advanced 
stage chemorefractory NSCLC patients with the goal of evaluating the effects of 
targeted therapies based on KRAS-mutated lung tumors (116). Since the majority of 
enrolled cases were lung adenocarcinomas, we focused our studies on this lung 
cancer subtype and identified a subgroup (17%) of advanced stage patients with 
RICTOR genomic alterations (mutations or amplifications). RICTOR’s precise role in 
the context of NSCLC has not been extensively evaluated. A recent study classified 
RICTOR amplifications as a novel subset of patients with lung cancer that may 
respond to dual mTORC1/2 inhibitors (117). To expand on this finding, we were 
interested to further define settings where RICTOR or RICTOR-associated signaling 
blockade in combination with targeted therapy may enhance response in metastatic 
disease and improve outcome.  
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Therefore, the proposed hypothesis is that RICTOR alterations promote 
oncogenic properties and RICTOR-associated signaling blockade could serve as an 
effective therapeutic strategy in KRAS mutant NSCLC.  
To pursue this hypothesis, the following specific aims were developed: 
 Specific Aim 1: To assess the prevalence of RICTOR alterations in 
early and advanced stage NSCLC and determine if these alterations 
correlate with clinical outcome. 
 Specific Aim 2: To determine the phenotypic consequences of RICTOR 
knockdown in in vitro and in vivo NSCLC models. 
 Specific Aim 3: To evaluate the potential therapeutic benefit of 
RICTOR-associated signaling blockade in pre-clinical NSCLC models. 
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Chapter 2 
Materials and Methods 
Cell lines and reagents 
NSCLC cell lines (H23, H2009, H1792, H1650, H3122, H2172, H2126, A549, 
HCC44, CALU6, HCC193, and H1819) were either obtained from American Type 
Tissue Collection (ATCC, Manassas, VA) or were obtained from collaborators and 
authenticated via STR DNA fingerprinting at the University of Texas MD Anderson 
Characterized Cell Line Core (CCLC). All cell lines were grown in RPMI 1640 
supplemented with 10% FBS (Cellgro, Mediatech, Manassas, VA) with no antibiotics. 
Whole genome single nucleotide polymorphism (SNP) array profiling (previously 
described (118)) was obtained for the cell line panel to determine RICTOR amplified 
(copy number variation (CNV ≥ 3.5) and non-amplified cell lines (CNV = 2). 
Immortalized human bronchial epithelial cells (HBEC) expressing wild-type KRAS 
(HBEC3-KT) or KRAS-mutant with stable p53 knockdown (HBEC3-KT53KC12) cell 
lines were provided by Drs. Adi Gazdar and John Minna (University of Texas 
Southwestern Medical Center, Dallas, TX) and maintained in keratinocyte-SFM 
medium with bovine pituitary extract and human recombinant epidermal growth factor 
(Invitrogen). Generation of stable RICTOR knockdown cell lines were developed 
using pTRIPZ inducible lentiviral shRNA-encoding plasmids (RICTOR shRNA 
#RHS4696, Non-silencing shRNAmir Control (NTC) #RHS4743) (GE Dharmacon, 
Lafayette, Colorado) for the inducible knockdown of RICTOR in the presence of 
2μg/mL doxycycline hyclate (SIGMA) and were selected with 2μg/mL puromycin 
(SIGMA). RFP expression was also utilized for monitoring transduction and 
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knockdown efficiency. Targeted inhibitors AZD2014 (vistusertib), AZD6244 
(selumetinib), and GSK1120212 (trametinib) were obtained from Selleck Chemicals 
(Houston, TX) and dissolved in DMSO to create stock solutions. All additional 
dilutions were performed using the respective cell culture medium for working 
concentrations. 
Immunoblotting and antibodies 
Western blotting analyses were performed on total protein lysates extracted 
from NSCLC cell lines. In brief, cell cultures were washed with ice-cold phosphate 
buffered saline (1X PBS) containing protease and phosphatase inhibitor tablets 
(Roche, Basel, Switzerland) and homogenized in 1X RIPA buffer (SIGMA-Aldrich, St. 
Louis, MO). The cells were scraped and samples were centrifuged at 14,000 rpm for 
25 minutes at 4C and protein concentrations of supernatants were quantified by DC 
Protein Assay per manufacturer’s instructions (Bio-Rad, Hercules, CA). Equal 
amounts of protein were separated by pre-cast 4-15% gradient gels (Bio-Rad) via 
SDS-PAGE and transferred onto nitrocellulose membranes using the Trans-Blot 
Turbo Transfer System (Bio-Rad). Membranes were blocked with 5% milk for 1 hour, 
and all washes were in TBS-T. The membranes were incubated with the following 
commercial antibodies: RICTOR, p-RICTOR (Thr1135), p-AKT (Ser473), AKT, p-
MEK1/2 (Ser217/221), MEK1/2, p-p44/42 MAPK (Thr202/Tyr204) (p-ERK1/2), 
ERK1/2, c-PARP, PARP, p-mTOR (S2481), mTOR, p-NDRG1 (Thr346), NDRG1, 
mSIN1 are from Cell Signaling Technologies (Danvers, MA); β-actin-HRP (used as 
equal loading control) and p-PKCα (Ser657) are from Santa Cruz Biotechnology 
(Santa Cruz, CA). Secondary antibodies included horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse antibodies obtained from Cell Signaling Technologies. 
30 
 
Immunoreactivity was visualized by use of Western Lightning Plus-ECL (Perkin-
Elmer, Waltham, MA) and exposure to x-ray film according to manufacturer 
instructions. Densitometric quantification of bands was performed using Image Studio 
Lite 5.0 software (Lincoln, Nebraska). 
siRNA knockdown studies 
Knockdown studies were performed using ON-TARGETplus SMARTpool 
siRNAs targeting the gene of interest at a final concentration of 30 nmol/L using 
DharmaFECT I transfection reagent (GE Dharmacon, RNAi Technologies, Thermo). 
ON-TARGETplus Non-targeting siRNA pools served as negative controls. siRNAs 
were prepared using Opti-MEM I serum free media (ThermoFisher), and added to 
culture dishes for 24 hours. Fresh complete media was replaced after 24 hours and 
incubation continued for a total of 72-96 hours before downstream analysis. 
Cell viability assays 
For MTS assay testing cell viability, NSCLC cells were seeded in octuplicate at 
a density of 2,000 cells per well in 96-well plates. An endpoint viability assay was 
performed using MTS assay (3-4, 5-dimethyl-thiazol-2-yl)-5-(3-
carboxymethoxyphenyl-2-(4-solfophenyl)-2H-tetrazolium, inner salt) at the indicated 
time points according to the manufacturer’s protocol (Promega, Madison, WI). For 
experiments evaluating the effect of RICTOR knockdown with mTORC1/2 and/or 
MEK1/2 inhibitors, the crystal violet staining and MTT dye reduction method was 
used. Stable inducible shRICTOR cell lines were seeded at 2x104 cells per well in 6-
well plates in the presence of 2μg/mL doxycycline. The next day, each well was 
treated with either selumetinib, trametinib, AZD2014, or DMSO (control) at the 
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indicated concentrations and incubation was continued for a further 7 to 10 days, with 
drug/media changed every 3 days. MTT solution (Methylthiazolyldiphenyl-tetrazolium 
bromide, 1mL per well, 2mg/mL; SIGMA-Aldrich) was added to each well, followed by 
incubation for 2-3 hours at 37°C. The media was then removed and the dark blue 
crystals in each well were dissolved in 400μL of DMSO and transferred to 96-well 
plates. Absorbance was measured at test and reference wavelengths of 550 and 630 
nm, respectively, using a FLUOstar Omega microplate reader (BMG LABTECH, 
Ortenberg, Germany). The percentage of cell viability is shown relative to untreated 
controls. 
Cell proliferation assay 
 Cell proliferation was performed using stably transduced shRICTOR cell lines 
(H23, H2009, H1792) by seeding 4x105 cells in 10cm dishes in +/- doxycycline 
containing media. Time points were analyzed at 4, 8, 12, and 16 days of continuous 
shRICTOR (+doxycycline) treatment to evaluate the effects of RICTOR knockdown. 
Total cell number was counted and recorded using the Cellometer K2 Image 
Cytometer (Nexcelom, Lawrence, MA). A fixed ratio of cells was subsequently split 
into new dishes and sub-cultured for the indicated time points of the experiment. 
Cell cycle analysis 
 For cell cycle analysis, cells were harvested via trypsinization, washed with ice-
cold 1X PBS, and fixed with 70% ice-cold ethanol. Fixed cells were then re-washed, 
treated and stained with propidium iodide/RNase using the Propidium Iodide Flow 
Cytometry Kit (Abcam, Cambridge, UK) per manufacturer’s protocol. Stained cells 
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were immediately analyzed using the BCI Gallios Analyzer flow cytometer (Beckman 
Coulter, Brea, CA). 
Human p-MAPK Array 
A Proteome Profiler Array (Human Phospho-MAPK Array Kit) (R&D Systems, 
Inc., Minneapolis, MN) was used to assess the relative level of phosphorylation of 26 
kinases involved in the three major families of MAPK pathways. Array was performed 
according to manufacturer’s instructions. H23 cells were treated with either NTC or 
siRICTOR for 72 hours, and the cells were subjected to lysis using the buffer provided 
in the kit. The arrays were then blocked with blocking buffer and incubated with the 
cell lysates (300 µg/sample) overnight at 4C. The next day, arrays were washed and 
incubated with a biotinylated antibody for 2 hours, washed, and incubated with a 
streptavidin-horseradish-peroxidase-conjugated detection antibody, treated with 
Western Lightning Plus-ECL, and exposed to x-ray film. 
Clonogenic survival assay  
NSCLC cells were seeded in 6-well plates (250-500 cells per well) in the 
presence or absence of 2μg/mL doxycycline for inducible shRICTOR cell lines or non-
targeting control (or siRNA against RICTOR) for 2-3 weeks, with change of media 
every 2-3 days. After the endpoint, wells were washed with PBS and fixed with 4% 
paraformaldehyde for 10 minutes, followed by staining with 0.05% crystal violet for 30 
minutes. Stained wells were then washed thoroughly with water to clear any unbound 
crystal violet. Colony area was calculated using Image J software (NIH, Bethesda, 
Maryland) to determine percentage area stained relative to control. Soft agar assay 
testing anchorage independent growth was performed using Millipore’s Cell 
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Transformation Detection Assay per manufacturer’s recommendations (Merck KGaA, 
Darmstadt, Germany). In brief, 6-well plates were prepared with 0.8% base agar layer 
and allowed to solidify. 2,500 cells/well were resuspended in 0.4% top agar solution 
and aliquoted appropriately on top of the base agar layer (pre-warmed to 37C). 
Doxycycline containing media was used to induce continuous shRICTOR knockdown 
compared to NTC. Cells were incubated for 21-28 days at 37°C until colonies were 
formed, with frequent media change every 3 days. Colonies were then visualized with 
the accompanied cell stain solution and quantified with the cell quantification solution 
by measuring absorbance at 490nm. A well containing only base and top agar layers 
without cells served as background control for quantification. 
Migration and Invasion assays 
The cell migration assay was performed using a 24-well transwell plate with 
8μm polyethylene terephthalate (PET) membrane filters (Corning Inc., Corning, NY) 
that separate the top and bottom culture chambers. In brief, respective NSCLC cell 
lines were transfected with siRNA targeting RICTOR for 72 hours, harvested, and 
plated in the upper chamber at a density of 20,000 cells per well in 500μL of 0.5% 
reduced serum RPMI 1640 media. The bottom chambers contained 750μL of either 
5% serum (serves as chemoattractant) or 0.5% reduced serum conditions. Cells were 
allowed to migrate for 24 hours, and filters were then removed and non-migrant cells 
on the upper side were wiped away with use of a cotton swab. Filters were fixed and 
stained using the Diff-Quik Stain Set Kit (Siemens Healthcare Diagnostics, Newark, 
DE) per manufacturer’s protocol and mounted onto microscope slides. Five random 
fields were quantified at 10X objective lens in a light microscope, and results are 
displayed as the average number of cells migrated. The cell invasion assay was 
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similar to the described protocol above, except that the transwell chambers used were 
Corning BioCoat Growth Factor Reduced Matrigel invasion chambers and cells were 
fixed and stained after 48 hours of incubation. 
Xenograft tumor models 
All animal procedures and care were approved by the MD Anderson Cancer 
Center Institutional Animal Care and Usage Committee. Animals received humane 
care as per the Animal Welfare Act and the NIH “Guide for the Care and Use of 
Laboratory Animals”. For tumorigenicity studies evaluating the effects of RICTOR 
knockdown, H1792 and H23 stable shRICTOR inducible cell lines were expanded and 
harvested, washed, and pre-cooled in serum-free RPMI 1640 medium mixed 1:1 with 
Corning growth factor reduced Matrigel Matrix (Corning, NY). Female athymic nude 
mice, between 6-8 weeks old, were injected subcutaneously in the flank with H1792 
(2x106) or H23 (5x106) shRICTOR cells. Mice were divided into two groups with 6 
mice per arm:  doxycycline feed (600mg/kg; BioServ, Flemington, NJ) immediately 
after inoculation of cells, or control group (regular feed). Tumors were measured twice 
weekly with a digital caliper, and size was calculated as (length x width2/2). The mice 
were euthanized and the tumors were collected for protein lysate analysis. Protein 
lysates were prepared by homogenization using the Precellys24 tissue homogenizer 
(Bertin Instruments, France).  
For studying the effects of drug treatments on xenograft growth, H1792 
shRICTOR cells (4x106) were prepared as described above and injected 
subcutaneously in the flanks of 6-8 week old female athymic nude mice. After the 
average tumor volumes reached 100mm3, mice were randomized into 1 of 5 
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treatment arms (6 mice/arm), and the indicated treatment regimens were performed 
by oral gavage for 22 days. The treatment arms consisted of: vehicle (1% tween-80, 
bid), selumetinib (25mg/kg, bid), selumetinib (25mg/kg, bid) + doxycycline feed 
(600mg/kg), AZD2014 (15mg/kg, qd), and selumetinib + AZD2014 (equivalent 
dosages used as per individual inhibitor treatments). Selumetinib was obtained from 
Selleck Chemicals and AZD2014 was obtained from MedChem Express (Monmouth 
Junction, NJ). Tumor volumes and body weights were recorded twice weekly. Tumors 
were extracted on the final day 3 hours following the last treatment, and protein 
lysates were prepared as described above.  
Clinical datasets and patient sample characteristics  
A total of 3 datasets were analyzed independently in our study: the Biomarker 
Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE-2, 
n=92 lung adeno cases with mutation data; n=107 lung adeno cases with mRNA 
expression data), The Cancer Genome Atlas (TCGA Lung Adenocarcinoma, n=230 
with mutation cases, n=496 with mRNA expression data), and Profiling of Resistance 
Patterns and Oncogenic Signaling Pathways in Evaluation of the Thorax 
(PROSPECT, n=151). The BATTLE-2 trial is a randomized phase II, multi-center 
biopsy-mandated and biomarker-based clinical trial of targeted therapy in advanced 
stage chemorefractory NSCLC (116). Clinical and genomic data for 230 mostly early-
stage, surgically resected lung adenocarcinomas that were analyzed in the TCGA 
dataset was obtained from the cBio Cancer Genomics Portal and GDC data portal 
(https://gdc.nci.nih.gov/) (119, 120). The PROSPECT dataset includes surgically 
resected tumor tissue collected from patients with lung adenocarcinoma at MD 
Anderson Cancer Center. Bioinformatics analyses and support was provided by Dr. 
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Jing Wang and Li Shen (Department of Bioinformatics and Computational Biology, 
MD Anderson Cancer Center). 
Statistical analyses  
The results presented are the average of at least two experiments each 
performed at least in triplicate. Data obtained from cell culture assays were 
summarized using descriptive and inferential statistical analyses accompanied by 
graphs and conducted by using GraphPad Prism 6 (GraphPad Software, La Jolla, 
CA). Differences between groups were calculated by the t-test unless otherwise 
noted. A P-value < 0.05 was considered significant. Cox hazard proportional models 
were applied for association between mRNA expression and overall survival. 
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Chapter 3 
Results 
3.1 Identification of RICTOR alterations in advanced NSCLC 
NSCLC is biologically and genomically diverse and has differing responses to 
standard chemotherapy and targeted therapy developed to inhibit key molecular 
aberrations that drive cancer progression. However, over 30% of lung 
adenocarcinomas that are diagnosed have alterations that do not have a therapeutic 
target. In an effort to identify novel potentially actionable targets in advanced stage 
NSCLC, we utilized genomic profiling from an ongoing clinical trial termed the 
Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination 
(BATTLE-2) as a platform for our studies. The BATTLE-2 was a phase II trial that 
specifically targeted advanced stage, chemorefractory NSCLC patients who have 
failed at least one prior chemotherapeutic regimen (116).  Patients were adaptively 
randomized by KRAS status to one of four treatment arms: erlotinib (EGFRi), erlotinib 
plus MK2206 (AKTi), MK2206 plus selumetinib (AZD6244; MEKi), or sorafenib 
(RAFi/VEGFRi) (Figure 6). Prospective biopsies based on specified tumor markers 
were utilized for adaptive randomization to assign patients to the treatment arm with 
the most potential benefit on the basis of cumulative data at the time. Molecular 
profiling was performed on all acquired biopsies via the FoundationOne hybridization 
capture-based next-generation sequencing (NGS) test which evaluated over 182 
cancer-related genes (Foundation Medicine, Inc.).  
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Figure 6. Identifying novel actionable targets in refractory NSCLC using the 
BATTLE-2 clinical trial. The Biomarker-Integrated Approaches of Targeted Therapy 
for Lung Cancer Elimination (BATTLE-2) is a phase II trial that specifically targets 
advanced stage, chemorefractory KRAS mutated NSCLC patients that have failed at 
least one prior chemotherapeutic regimen. Exclusion criteria included tumors with 
sensitizing EGFR mutations or ALK gene fusions if they had not been previously 
treated with erlotinib or crizotinib. Patients agree to a baseline tumor biopsy (for 
biomarker analysis) and were adaptively randomized by KRAS status to one of four 
treatment arms: erlotinib (EGFRi), erlotinib plus MK2206 (AKTi), MK2206 plus 
selumetinib (AZD6244, MEKi), or sorafenib (RAFi, VEGFRi). The primary endpoint 
was 8-week disease control rate based on Response Evaluation Criteria in Solid 
Tumors (RECIST). The specific nodes of the pathways targeted are illustrated.  
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The detailed protocol and analysis of the NGS assay has been previously reported 
(121). The frequency of selected genes identified from the NGS targeted panel that 
carry mutations and/or amplifications are shown in Figure 7, which includes the entire 
NSCLC BATTLE-2 cases sequenced. The criteria used to identify potentially 
actionable targets were to first identify genes that were amplified or mutated, followed 
by if they were targetable. We focused our attention on RICTOR alterations as they 
have not been extensively studied in the context of NSCLC and are present at a 
relatively high frequency, suggesting possible actionability.
 
Figure 7. Frequency of potentially actionable genes that carry mutations and/or 
amplifications from the NGS FoundationOne targeted panel. The percentage 
shown is out of 159 NSCLC cases that have mutation/copy number alteration data. 
Frequently altered genes, such as KRAS and EGFR, were excluded from this graph 
since these were not novel targets. Genes are listed in Abbreviations section. The 
frequency of RICTOR gene alterations (~13.2%, 21/159) is highlighted in blue. 
  Moreover, we filtered our studies to lung adenocarcinoma cases since the 
majority of the enrolled patient population in the BATTLE-2 trial were of this NSCLC 
subtype. A total of 92 chemorefractory lung adenocarcinoma tumor biopsies have 
undergone NGS profiling. We identified RICTOR gene alterations in a total of 17.4% 
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(16/92) of cases, including 11.9% amplifications (11/92) and 5.4% mutations (5/92), 
which were mutually exclusive (Figure 8A, left).  
 
A) 
 
B)  
 
Figure 8. RICTOR alterations are present in early and advanced stage lung 
adenocarcinomas at similar frequencies. (A) Summary of frequency of RICTOR 
gene alterations (mutations or amplifications) in chemorefractory advanced lung 
adenocarcinoma samples (BATTLE-2, n=92) and in early stage lung adenocarcinoma 
samples (TCGA, n=230) (8). (B) Schematic of novel RICTOR gene mutations from the 
BATTLE-2 NSCLC cohort and number of mutant cases. 
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Mutations in the RICTOR gene have not been previously identified, particularly the 
functional roles of these mutations. Figure 8B illustrates the location along the 
RICTOR gene in which these novel mutations occur. The significance of these 
RICTOR mutations are yet to be determined, as the crystal structure of RICTOR has 
not been elucidated and current bioinformatics tools have failed to identify functional 
domains of this scaffold protein. However, a recent study attempted to shed light into 
RICTOR’s poorly understood domain architecture by searching for conserved regions 
to assign structural and functional domains (122). The study identified that similar to 
its counterpart RAPTOR, RICTOR also has HEAT, WD40, and PH domains that might 
be utilized for common motif binding to mTORC, mediating cellular localization and 
transmission of signaling to downstream effectors. Although this is the first such report 
analyzing RICTOR’s domain structure, experimental confirmation is still needed to 
validate these findings.  
Furthermore, to determine whether RICTOR alterations are an early event in 
lung cancer progression, we surveyed the frequency of alterations in early stage lung 
adenocarcinoma cases utilizing The Cancer Genome Atlas (TCGA) database (120, 
123). We identified a similar frequency of a total 13.4% (31/230) of RICTOR-altered 
cases, which included 10% amplifications (25/230) and 5.2% mutations (12/230). 
Interestingly, in contrast to the BATTLE-2 advanced stage tumors, some early stage 
tumors from the TCGA incurred concomitant amplifications and mutations (Fig. 8A, 
right). In addition, in surveying the frequency of RICTOR alterations across various 
cancer types, we found the highest prevalence of alterations in NSCLC, particularly 
lung adenocarcinoma, compared to other reported tumor types (Figure 9). 
  
42 
 
 
  
Figure 9. Cross-cancer mutational frequency of RICTOR in the TCGA 
database. cBioPortal query across various cancer types for RICTOR DNA 
mutation frequencies. Alteration frequency is displayed as a histogram across 
reported cancer studies. NSCLC datasets are marked with an asterisk, showing 
lung adenocarcinoma as the most frequently mutated tumor type. Database 
accessed on November 18, 2016. 
* 
* 
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3.2 RICTOR mRNA expression is higher in RICTOR amplified than non-amplified 
NSCLC 
We next evaluated the correlation between RICTOR amplification and RICTOR 
gene expression in our two datasets. There was a significant direct correlation 
between RICTOR gene amplification and RICTOR mRNA expression in the early 
stage TCGA dataset, and a trend seen in the advanced stage BATTLE-2 lung 
adenocarcinoma cases (Figure 10). Of note, when we performed this analysis 
including all NSCLC subtypes from the BATTLE-2 cases (total of 159 cases with DNA 
NGS profiling), there was statistical significance of direct correlation between RICTOR 
gene amplification and RICTOR mRNA expression (data not shown), suggesting that 
the sample size in the BATTLE-2 adenocarcinoma was too small to reach statistical 
significance. 
Figure 10. Correlation of RICTOR amplification to mRNA gene expression in 
lung adenocarcinoma cases. Correlation of RICTOR amplified vs. non-amplified 
cases to RICTOR mRNA (log2) expression levels in BATTLE-2 (n=92) (left) and 
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TCGA (n=230) (right) datasets. Red circle = amplified RICTOR case; blue circle = 
non-amplified RICTOR case. 
3.3 Associating RICTOR mRNA expression to clinical outcome 
To determine the association of RICTOR alterations to clinical outcome, we 
performed a univariate overall survival (OS) analysis of RICTOR mRNA expression in 
lung adenocarcinoma patients using the Cox proportional hazards model. As shown in 
Table 1, there is significantly worse overall survival in patients with advanced stage 
lung adenocarcinoma in the BATTLE-2 cases (OS, hazard ratio [HR]: 1.73, 95% 
confidence interval [CI]: 1.23-2.42, P=0.0015). We also saw a worse prognosis in our 
early stage surgically resected lung adenocarcinoma cases from the PROSPECT 
dataset (OS, HR: 1.54, 95% CI: 1.03-2.29, P=0.0337); however, no significance was 
seen in patients from the TCGA dataset.  
Table 1. Univariate overall survival analysis of RICTOR mRNA expression in 
lung adenocarcinoma patients by Cox proportional hazards model 
Study HR (95% CI) P-value 
BATTLE-2 Trial (n=107) 1.73 (1.23-2.42) 0.0015 
PROSPECT (n=151) 1.54 (1.03-2.29) 0.0337 
TCGA (n=496) 1.05 (0.81-1.37) 0.675 
Abbreviations: HR, hazard ratio; CI, confidence interval. 
 
3.4 Surveying the co-mutational landscape of RICTOR alterations 
We next explored the co-mutational landscape of RICTOR-altered cases using 
the TCGA lung adenocarcinoma dataset to determine enrichment of specific pathway 
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alterations that are known to be aberrantly regulated in lung cancers. We surveyed 
the percent alterations (mutations and/or copy number changes) in several key genes 
that play important roles in mediating pathways such as receptor tyrosine kinase 
(RTK) signaling, mTOR signaling, MAPK signaling, and oxidative stress response. 
The specific gene alterations and frequencies are listed in Table 2. As depicted in 
Figure 11, there were significantly higher PTEN co-mutant cases in the RICTOR-
altered group, suggestive of a hyperactive PI3K/RICTOR/AKT pathway. Interestingly, 
there was mutual exclusivity between RICTOR alterations and STK11 mutations in 
both the TCGA and BATTLE-2 datasets. We found an enrichment of alterations 
(mutations and/or amplifications) in several key genes of the MAPK pathway in 
RICTOR-altered cases compared to the rest. There was a notably high percentage of 
KRAS, NF1, BRAF/CRAF alterations in the RICTOR-altered cases. These data 
suggest that RICTOR expression could be an important co-oncogenic driver in lung 
cancer progression, and thus we focused our efforts on characterizing the importance 
of RICTOR, specifically in KRAS mutant settings. 
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Figure 11. Surveying the co-mutational landscape of RICTOR-altered cases. 
Selected pathways are shown with percentages of gene alterations (mutations and/or 
copy number changes) extracted from the lung adenocarcinoma dataset of the 
cBioPortal for Cancer Genomics. The percentages of gene alterations in RICTOR-
altered cases (outside parenthesis) are compared to non-altered cases (inside 
parenthesis).  
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Table 2. List of co-mutant genes and their frequency of alterations (TCGA LuAd) 
Gene 
Type 
of Alt 
# in RICTOR 
 alt (%) 
(out of 31) 
# in RICTOR 
un-alt (%) 
(out of 199) 
Log 
ratio 
p-value q-value Tendency 
EGFR 
mut 4 (12.9%) 29 (14.57%) -0.18 0.531 0.865 Mut exclusivity 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mut exclusivity 
amp 3 (9.68%) 12 (6.03%) 0.68 0.328 0.801 Co-occurrence 
ERBB2 
mut 2 (6.45%) 4 (2.01%) 1.68 0.187 0.733 Co-occurrence 
amp 1 (3.23%) 5 (2.51%) 0.36 0.585 0.865 Co-occurrence 
MET 
mut 1 (3.23%) 18 (9.05%) -1.49 0.24 0.733 Mutual exclusivity 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
amp 3 (9.68%) 5 (2.51%) 1.95 0.0777 0.629 Co-occurrence 
ALK mut 3 (9.68%) 15 (7.54%) 0.36 0.448 0.865 Co-occurrence 
RET 
mut 1 (3.23%) 8 (4.02%) -0.32 0.652 0.865 Mutual exclusivity 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
ROS1 
mut 3 (9.68%) 9 (4.52%) 1.1 0.209 0.733 Co-occurrence 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
KRAS 
mut 8 (25.81%) 67 (33.67%) -0.38 0.257 0.748 Mutual exclusivity 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
amp 1 (3.23%) 12 (6.03%) -0.9 0.455 0.865 Mutual exclusivity 
NRAS 
mut 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
del 0 (0.00%) 4 (2.01%) <-10 0.558 0.865 Mutual exclusivity 
amp 1 (3.23%) 1 (0.50%) 2.68 0.252 0.703 Co-occurrence 
HRAS 
mut 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
RIT1 
mut 0 (0.00%) 5 (2.51%) <-10 0.482 0.865 Mutual exclusivity 
amp 5 (16.13%) 27 (13.57%) 0.25 0.439 0.865 Co-occurrence 
NF1 
mut 9 (29.03%) 18 (9.05%) 1.68 3.93E-03 0.324 Co-occurrence 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
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amp 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
BRAF 
mut 4 (12.90%) 18 (9.05%) 0.51 0.342 0.83 Co-occurrence 
amp 3 (9.68%) 3 (1.51%) 2.68 0.0336 0.475 Co-occurrence 
RAF1 mut 1 (3.23%) 1 (0.50%) 2.68 0.252 0.733 Co-occurrence 
MAP2K1 
mut 0 (0.00%) 3 (1.51%) <-10 0.646 0.865 Mutual exclusivity 
amp 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
KEAP1 
mut 4 (12.90%) 36 (18.09%) -0.49 0.338 0.83 Mutual exclusivity 
del 0 (0.00%) 4 (2.01%) <-10 0.558 0.865 Mutual exclusivity 
CUL3 
mut 1 (3.23%) 3 (1.51%) 1.1 0.442 0.865 Co-occurrence 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
amp 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
NFE2L2 
mut 0 (0.00%) 4 (2.01%) <-10 0.558 0.865 Mutual exclusivity 
amp 1 (3.23%) 5 (2.51%) 0.36 0.585 0.865 Co-occurrence 
PTEN 
mut 2 (6.45%) 1 (0.50%) 3.68 0.0485 0.612 Co-occurrence 
amp 2 (6.45%) 2 (1.01%) 2.68 0.0888 0.629 Co-occurrence 
PIK3R1 
mut 0 (0.00%) 2 (1.01%) <-10 0.748 0.865 Mutual exclusivity 
del 0 (0.00%) 3 (1.51%) <-10 0.646 0.865 Mutual exclusivity 
PIK3CA 
mut 1 (3.23%) 14 (7.04%) -1.12 0.372 0.863 Mutual exclusivity 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
amp 2 (6.45%) 3 (1.51%) 2.1 0.136 0.629 Co-occurrence 
AKT1 
mut 0 (0.00%) 2 (1.01%) <-10 0.748 0.865 Mutual exclusivity 
del 0 (0.00%) 1 (0.50%) <-10 0.865 0.865 Mutual exclusivity 
amp 0 (0.00%) 2 (1.01%) <-10 0.748 0.865 Mutual exclusivity 
STK11 
mut 0 (0.00%) 40 (20.10%) <-10 1.67E-03 0.262 Mutual exclusivity 
del 0 (0.00%) 3 (1.51%) <-10 0.646 0.865 Mutual exclusivity 
TCGA cBioPortal calculates Log ratio = Log2 based ratio of (% in altered / % in unaltered);  
p-value derived from Fisher Exact Test; q-value derived from Benjamini-Hochberg procedure. 
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Chapter 4 
Results 
4.1 Selection and mutational background of RICTOR cell line panel  
 In order to study the oncogenic effects imposed by RICTOR, we established a 
RICTOR cell line panel by first screening 57 NSCLC cell lines to detect RICTOR copy 
number variations (CNVs) by utilizing a single nucleotide polymorphism (SNP) array 
(Figure 12). We selected seven RICTOR amplified (highlighted in red arrows) and five 
non-amplified cell lines (highlighted in black arrows) that span diverse co-mutational 
backgrounds, including several lines that harbor KRAS, PTEN, PIK3CA, STK11, 
and/or EGFR mutations. The mutational background of the cell line panel used in our 
studies is summarized in Table 3. RICTOR amplified cell lines chosen were H23, 
H3122, H1792, H2009, H1650, H2172, H2126 and non-amplified cell lines were 
HCC193, H1819, A549, CALU6, and HCC44. 
 Moreover, in order to perform experiments that require extended duration for 
completion, we established several stable inducible shRICTOR cell line models 
(Figure 13). These cell lines possess puromycin resistance and inducible red 
fluorescence protein (RFP) expression for selection and visualization of transduction 
efficiency, respectively. Upon administration of doxycycline, we see a significant 
reduction in the RICTOR protein expression levels in the selected cell lines. 
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Figure 12. Selection of RICTOR cell line panel used for in vitro studies. Whole 
genome single nucleotide polymorphism (SNP) array profiling was obtained for 57 
NSCLC cell lines to determine RICTOR amplified (copy number variation (CNV ≥ 3.5) 
and non-amplified cell lines (CNV ~2). Seven RICTOR amplified cell lines (red arrows) 
and five RICTOR-non-amplified cell lines (black arrows) were selected. Copy number 
variation (CNV) values: red = amplified; black = diploid; green = deletion. 
 
 
 
 
 
 
Figure 13. Establishment of inducible shRICTOR cell line models. Several cell 
lines from the RICTOR cell line panel were used to establish tet-ON inducible 
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shRICTOR cell line models. pTRIPZ plasmid (Dharmacon) was used to stably 
transduce the indicated cell lines, and puromycin and RFP was used for positive clone 
selection. Doxycycline was used to stably knock down RICTOR in the cells, following 
dose and time optimization. Ideal knockdown was seen after doxycycline 
administration (2 µg/mL) for 96-144 hours depending on the cell line. Non-targeting 
control (NTC) was used as a doxycycline and transduction negative control, and β-
actin used as a loading control for Western blotting. 
 
Table 3. Mutational profile of RICTOR NSCLC cell line panel. 
 
 
 
 
 
  
 
Cell line KRAS EGFR STK11 PIK3CA PTEN EML4/ALK 
R
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e
d
 H2172 WT WT WT WT WT WT 
H2126 WT WT Mut WT WT WT 
H23 mut - G12C WT Mut WT Mut WT 
H3122 WT WT WT WT WT Mut 
H1792 mut - G12C WT WT WT WT WT 
H1650 WT Mut WT Mut Mut WT 
H2009 mut - G12A WT WT WT WT WT 
R
IC
T
O
R
  
n
o
n
-a
m
p
li
fi
e
d
 HCC193 WT WT WT WT WT WT 
H1819 WT WT WT WT WT WT 
A549 mut - G12S WT Mut WT WT WT 
Calu6 mut - Q61K WT WT WT WT WT 
HCC44 mut - G12C WT Mut WT WT WT 
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4.2 RICTOR signaling in RICTOR amplified versus non-amplified cell lines 
 After selecting our cell lines that carry additional secondary mutations, 
representative of the complex heterogeneity of NSCLC, we wanted to assess the 
signaling patterns associated with these cells at basal level. Figure 14 shows western 
blotting analysis of the signaling patterns seen in the amplified (shown in red) versus 
the non-amplified (shown in black) cell lines. We noticed several key 
 
 
 
Figure 14. Comparison of signaling and RICTOR expression in amplified versus 
non-amplified cell lines. (Left) Cell lysates from 12 NSCLC cell lines (amplified or 
non-amplified for RICTOR) were examined by Western blotting. Total and phospho-
specific antibodies used were for levels of RICTOR, mSIN1, p-AKT (S473), AKT, p-
PKCα (S657), p-NDRG1 (T346), NDRG1, p-mTOR (S2481), mTOR, and β-Actin as 
loading control. (Right) Quantification of relative RICTOR/β-Actin protein expression 
from densitometric analysis of western blot panel. *, P = 0.01. 
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trends that became apparent. First, RICTOR protein expression was significantly 
higher in the RICTOR amplified cell lines compared to the non-amplified cell lines. 
Densitometric analysis of relative RICTOR/β-Actin protein expression from the 
Western blot is shown on the right, and shows significantly higher RICTOR protein 
expression (*, P = 0.01). This is in concordance with our clinical analysis data from 
the TCGA and BATTLE-2 cohorts, showing that RICTOR amplification directly 
correlates with an overall higher RICTOR mRNA expression, suggesting that 
amplification of this gene drives the overexpression of the protein product. Next, we 
discovered that the expression of the mTORC2 component, mSIN1, is elevated in 
RICTOR amplified cells, suggesting increased rate of mTORC2 complex formation 
and potential activity (124). Additionally, increased mTORC2 activity markers were 
seen in our amplified cells, marked by an overall increase in p-PKCα S657 levels and 
elevated phosphorylation of N-myc downstream regulated gene 1 (p-NDRG1 T346), 
which serves as a surrogate marker for SGK1 activity (43).  Interestingly, although 
mTORC2 is predominately responsible for the phosphorylation of AKT on S473 
leading to full activation, our RICTOR amplified cell lines displayed variable degrees 
of basal AKT activity levels compared to our non-amplified cells. This could be 
attributed to the complex heterogeneity of these cell lines that induce signaling to the 
often-deregulated PI3K/AKT/mTOR pathway. Also, other AKT regulators have been 
shown to influence AKT activation such as DNA-dependent protein kinase (DNA-PK), 
ILK1, protein kinase CβII (PKCβII), PH domain leucine-rich repeat protein 
phosphatase (PHLPP), and ataxia-telangiectasia mutant (ATM), all shown to reflect 
the various cellular contexts in which AKT activity may be modulated (26, 125, 126).  
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4.3 RICTOR knockdown decreases colony formation and anchorage-
independent growth in amplified cells 
 We next sought to determine the phenotypic consequences of RICTOR 
knockdown in vitro. We utilized our established stably transduced doxycycline (doxy)-
inducible shRICTOR cell lines that are either amplified or not for RICTOR. Following 
RICTOR knockdown in our cell lines, colony formation potential was assessed after 2 
to 3 weeks and resulted in a significant reduction of colony growth in all 3 of our 
RICTOR amplified cell lines (H23, H2009, H1792), as measured by relative 
percentage of colony area compared to non-targeting control (NTC) (*, P < 0.05) 
(Figure 15, top). We did not see an effect in our non-amplified cell lines A549 and 
HCC193, suggesting that RICTOR amplifications provide a survival advantage to 
NSCLC cells driven by increased RICTOR expression. Additionally, when we 
performed an anchorage-independent growth assay to test the transformative ability 
of RICTOR by plating H23 cells on soft agarose and treating either NTC or shRICTOR 
cells with doxycycline to stably knock down RICTOR, there was complete abrogation 
of colony formation following RICTOR inhibition, again suggesting that RICTOR 
contributes proliferative properties to cells (Figure 15, bottom). 
4.4 RICTOR knockdown decreases cell proliferation in part through G0/G1 cell 
cycle arrest 
 Since we witnessed a dramatic reduction in the colony formation potential of 
cells following RICTOR knockdown, it was of interest to determine the precise role 
that RICTOR plays in regulating cell survival and/or proliferation. We therefore 
performed a cell proliferation assay by culturing cells in the presence or absence of  
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Figure 15. RICTOR knockdown decreases colony formation and anchorage-
independent growth in amplified cells. (Top) Colony formation assay of 3 RICTOR 
amplified cell lines (H23, H2009, H1792) and 2 non-amplified cell lines (A549, 
HCC193) comparing RICTOR knockdown to non-targeting control. Data are graphed 
as the mean percentage ± percent SD. (Bottom) Anchorage-independent growth 
assay in soft agar of stably transduced H23 cell line with RICTOR knockdown (A549 
serves as positive control). *, P < 0.05; n.s. = not significant. 
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doxycycline to induce RICTOR knockdown for an extended duration of time, and 
quantified total cell numbers at 4, 8, 12, and 16 days of incubation (Figure 16A). 
Results demonstrate that reducing RICTOR levels in the three cell lines tested 
markedly reduced the total cell numbers in as early as 4 to 8 days, and reduced the 
cell numbers by over 75% in all 3 cell types by day 16, yielding similar results to the 
colony formation assay (Figure 15). Moreover, we assessed whether this reduction in 
cell number was due to cell cycle changes. H23, H2009, and H1792 cell lines were 
cultured for 8 days with or without doxycycline, and stained with Propidium iodide (PI) 
for FACS cell cycle analysis. As seen in Figure 16B, RICTOR knockdown resulted in 
a slight G0/G1 cell cycle arrest in all 3 cell lines tested. Quantification of the cell cycle 
phases was performed and shows an increase of 10%, 11.7%, 4.9% G0/G1 cell cycle 
arrest in the shRICTOR cells compared to NTC cells of H23, H1792, and H2009, 
respectively (Figure 16C). Previous reports have linked RICTOR/mTORC2 to the 
regulation of the cell cycle through modulation of cyclin-D1 levels (115, 127-129). To 
test this, we performed Western blotting analysis on the H23 cell line to check for p-
AKT, p-MEK1/2, and cyclin-D1 levels (Figure 16D) following RICTOR knockdown via 
siRNA. We witnessed a slight decrease in the levels of Cyclin-D1 following RICTOR 
siRNA, providing a potential explanation of the modest increase seen in the G0/G1 cell 
cycle arrest. 
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A 
B C 
D 
Figure 16. RICTOR knockdown decreases the cell proliferative capacity. (A) 
Quantification of the relative cell number counts of shRICTOR cells relative to NTC 
cells at the indicated time points following doxycycline treatment. Complete cell 
counts were performed following 4, 8, 12, 16 days of incubation and shown as 
percentage relative to NTC. (B, C) Flow cytometry histograms and quantification of 
the phases of cell cycle in NTC versus shRICTOR cells following Propidium iodide 
(PI) staining and FACS sorting after 8 days of incubation. (D) Western blotting 
analysis of representative H23 cell line showing decreased cyclin-D1 expression. 
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4.5 RICTOR knockdown reduces the migration and invasion capacity of RICTOR 
amplified NSCLC cells  
To determine whether RICTOR plays a role in mediating migration and 
invasion of NSCLC cells, we utilized transwell in vitro migration and invasion assay 
chambers. These assays allow for the quantification of migratory and invasive cells 
that are able to move through specified pores of a filter membrane chamber placed in 
media containing a chemoattractant (e.g. FBS). After the cells were incubated for 24 
hours, the number of H23, H2009, and H1792 cells (RICTOR amplified, KRAS mutant 
cell lines) that migrated through the membranes of the chambers were significantly 
lower following RICTOR knockdown (>50%) in both serum reduced and normal serum 
conditions  (P ≤ 0.001) compared to NTC cells (Figure  17, top). Interestingly, H2172 
and H2126 (RICTOR amplified, KRAS wild-type cell lines) had a very poor basal 
migrative capacity, seen by the number of migratory control (NTC) cells quantified 
even in the absence of RICTOR knockdown (Figure 17, bottom). The results indicate 
that RICTOR knockdown reduces the migratory capability of RICTOR amplified 
NSCLC cell lines that possess KRAS co-mutations. 
 Similarly, the invasive capability was assessed using a Matrigel coated 
membrane filter chamber. After incubation of cells for 48 hours in either serum 
reduced or normal serum conditions, the number of cells that invaded through the 
membranous matrix were quantified. As seen in Figure 18 (top), H23, H2009, and 
H1792 cells had a significant reduction in the number of invasive cells following 
siRICTOR compared to NTC in both serum reduced and full serum conditions (P ≤ 
0.001).  H2009 had the most dramatic reduction in invasive ability (>80%) followed by 
H23 (>61%) and H1792 (>44%). Of note, similar to the migrative capacities, the 
59 
 
RICTOR amplified KRAS wild-type cell lines H2172 and H2126 had a very poor basal 
invasive capability, once again emphasizing the potential importance of mutant KRAS 
perhaps serving as a co-oncogenic driver with RICTOR to fuel these tumorigenic 
properties in these cell types. Taken together, these results show that RICTOR 
knockdown suppresses the migration and invasion efficiency of select NSCLC cell 
types.
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Figure 17. RICTOR knockdown reduces migration potential in RICTOR 
amplified cell lines. Cell migration was assessed using transwell chambers with 
8μm pore polyethylene terephthalate (PET) membrane filters. Cells were incubated 
in either reduced serum (0.5%) or normal serum (5%) for 24 hours. Representative 
visual images of the stained surfaces are shown. The results presented are an 
average of five random microscopic fields at 10X of the number of cells stained and 
counted. Data shown are of the means ± standard error of the means (SEM) of data 
from at least 3 independent experiments. *P = 0.001; **P < 0.001. 
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Figure 18. RICTOR knockdown reduces invasion potential in RICTOR amplified 
cell lines. Cell invasion was assessed using modified transwell chambers coated 
with growth factor reduced Matrigel with 8μm pore polyethylene terephthalate (PET) 
membrane filters. Cells were incubated in either reduced serum (0.5%) or normal 
serum (5%) for 48 hours. Representative visual images of the stained surfaces are 
shown. The results presented are an average of five random microscopic fields at 
10X of the number of cells stained and counted. Data shown are of the means ± 
standard error of the means (SEM) of data from at least 3 independent experiments. 
*P < 0.01; **P < 0.001; ns=not significant. 
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4.6 RICTOR knockdown results in reduced tumorigenicity in vivo 
Our data thus far suggests that RICTOR serves as an important oncogene 
involved in promoting various malignant phenotypes such as colony formation, 
migration and invasion. We wanted to investigate the role of RICTOR in vivo by use of 
murine xenografts engrafted with our established inducible shRICTOR lung 
adenocarcinoma cell lines H1792 and H23. There was a significant reduction in 
H1792 and H23 xenograft tumor growth following continuous induction of RICTOR 
knockdown by doxycycline administration compared to mouse control groups without 
treatment by 6 weeks (*, P < 0.05) (Figure 19 A, B). To assess the molecular 
signaling patterns following RICTOR blockade in vivo, we extracted total protein 
lysates from the tumor tissues of both the doxycycline treated and control groups from 
H1792 xenografts and performed Western blotting analysis. As seen in Figure 19C, 
RICTOR expression was significantly reduced in the +Doxy group and resulted in 
overall decreased p-AKT levels, in concordance with our in vitro results. In addition, p-
MEK1/2 and p-ERK1/2 levels were elevated in the RICTOR knockdown tumors, 
indicative of the compensatory mechanisms seen in vitro in our KRAS mutant cell 
lines. Taken together, genetic blockade of RICTOR is associated with growth 
inhibition in vivo, further supporting RICTOR’s role as an oncogenic driver in NSCLC. 
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Figure 19. RICTOR knockdown using RICTOR shRNA results in reduced 
tumorigenicity in vivo. (A, B) Athymic nude mice were inoculated with H1792 or 
H23 shRICTOR cell lines and were fed with either doxycycline (+Doxy, 600mg/kg) or 
control diet (-Doxy). Tumor volumes were measured twice weekly. Data points are 
presented as the mean tumor volume ± SEM. Representative images of xenograft 
tumors from each group before tumor harvesting are shown. *, P = 0.01; **, P < 0.01. 
(C) Lysates extracted from H1792 tumor xenografts were subjected to Western blot 
analysis with the indicated antibodies, showing RICTOR knockdown. 
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Chapter 5 
Results 
5.1 Compensatory MAPK signaling activation following RICTOR inhibition in 
KRAS mutant settings 
Our clinical analysis of RICTOR-altered cases from the TCGA dataset 
demonstrated an enrichment of MAPK pathway alterations (Figure 11). Thus, we 
wanted to determine possible changes in the cell signaling patterns of the 
RAS/RAF/MEK pathway affected by RICTOR. We performed knockdown studies via 
siRNA in several cell lines from our panel that harbor either RICTOR amplifications 
and/or KRAS mutations. Western blot analysis indicated that RICTOR siRNA 
effectively knocked down RICTOR protein expression levels in the respective samples 
(Figure 20A). Interestingly, siRICTOR treatment in RICTOR amplified NSCLC cell 
lines that harbor KRAS mutations (H23, H2009, H1792) resulted in a compensatory 
increased activation of the MAPK pathway seen by elevated levels of phosphorylated 
MEK (p-MEK1/2) compared to non-targeting control (NTC) treatment (Figure 20A). As 
expected, we saw a reduction in the full activation of AKT S473 (p-AKT) in these cells 
after RICTOR knockdown, associated with reduced mTORC2 activity. To determine if 
this compensation occurs specifically in KRAS mutant settings, we performed 
siRICTOR treatment on RICTOR amplified but KRAS wild-type cell lines (H1650, 
H2126, H2172), and results confirmed there was no significant increase in the p-
MEK1/2 levels. Of note, p-AKT levels were not reduced following RICTOR inhibition in 
H1650 (EGFR, PIK3CA, PTEN mutant) and H2126 (LKB1 mutant), which could be a 
result of their secondary mutations known to stimulate the PI3K/AKT/mTOR pathway. 
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Interestingly, a similar compensatory MAPK pathway activation was seen in RICTOR 
non-amplified but KRAS mutant cell lines (A549, HCC44), but not in KRAS wild-type 
cell lines (H1819, HCC193), suggesting that RICTOR amplification is not necessary 
for driving this compensatory mechanism. 
To further test our hypothesis that mutant KRAS is important in mediating this 
compensatory mechanism following RICTOR blockade, we performed double 
knockdown studies via siRNA targeting RICTOR and KRAS alone, or in combination. 
As seen in Figure 20B, in two of our RICTOR amplified KRAS mutant cell lines (H23, 
H1792), Western blotting results of siRICTOR showed an elevated activation of p-
MEK1/2, whereas siKRAS alone actually reduced the p-MEK1/2 levels and hence 
decreased MAPK pathway activity. When concomitant targeting of siRICTOR and 
siKRAS occurred, there was no increase in p-MEK1/2 levels, suggesting that there is 
an important interplay between RICTOR and mutant KRAS. Collectively, these 
findings suggest that there is a fine tuned balance of pro-survival signaling 
mechanisms in RICTOR/KRAS-altered settings, such that when the RICTOR pathway 
is blocked the cells tip the pro-survival balance to the parallel oncogenic MAPK 
pathway mediated by mutant KRAS, through increased activation of p-MEK1/2 
(Figure 20C). These data expose a unique therapeutic vulnerability in this specific 
setting where dual pathway targeted therapy approaches could be beneficial.  
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Figure 20. Compensatory MAPK signaling activation following RICTOR 
knockdown in KRAS mutant settings. (A) A panel of 6 RICTOR amplified and 4 non-
amplified NSCLC cell lines that are KRAS wildtype or mutant were transfected with 
siRNAs specific for RICTOR or scrambled negative control for 72 hours and cell 
lysates were analyzed by Western blotting for the specified proteins. (B) H23 and 
H1792 cells were transfected with siRNAs specific for RICTOR, KRAS, or scrambled 
negative control for 72 hours and cell lysates were analyzed by Western blotting for 
the specified proteins. (C) Potential model of compensatory mechanism between 
RICTOR and mutant KRAS. 
C 
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5.2 Compensatory MEK1/2 activation following RICTOR knockdown may be 
mediated through de-repression of inhibitory CRAF phosphorylation 
We next wanted to elucidate a potential mechanism behind the compensatory 
upregulation of p-MEK1/2, which occurs following RICTOR inhibition. We treated our 
H23 cell line (RICTOR amplified, KRAS mutant) with either siRNA directed against 
RICTOR or various mTOR/MAPK pathway inhibitors targeting mTORC1 (everolimus), 
mTORC1/2 (AZD2014), MEK1/2 (AZD6244, selumetinib), or a combination of 
AZD2014 and AZD6244 (Figure 21A). Whole-cell lysates were then extracted and 
probed with phosphorylation-specific antibodies for various PI3K/AKT/mTOR and 
MAPK pathway activation markers and Western blotting analysis was performed. In 
first assessing the full activation of AKT (p-AKT S473) under the different treatment 
conditions, siRICTOR treatment reduced the p-AKT levels as expected, with similar 
results seen after treatment with the dual mTORC1/2 inhibitor, AZD2014. Treatment 
with the mTORC1 inhibitor everolimus, however, increased the activity of AKT as 
previously reported (130, 131), most likely through attenuation of upstream feedback 
inhibition of IGF-1 receptor. To further confirm the specificity of the drugs and the 
subsequent downregulation of mTORC1 pathway activity, the p-S6RP levels were 
measured and were shown to be completely inhibited with everolimus or AZD2014 
treatment, but unchanged with the selective MEK1/2 inhibitor AZD6244, confirming 
that each drug was working selectively and inhibiting its respective pathway. 
Additionally, to reconfirm the compensatory activation of p-MEK1/2 after 
RICTOR inhibition, treatment of H23 cells with siRICTOR significantly increased the 
p-MEK1/2 levels compared to parental or NTC cells, as previously shown (Figure 
20A, B). Moreover, when AZD6244 was used to block MEK1/2 signaling, we saw a 
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significant reduction in the downstream p-ERK1/2 levels, reinforcing the specificity 
and downregulation of the MAPK pathway activity with this drug. Expectedly, there 
was also a dramatic increase in the p-MEK1/2 levels, as previously reported (132, 
133). This is because selumetinib does not disrupt the phosphorylated activation loop 
sites of MEK1/2, and therefore, treatment with this MEK inhibitor relieves a negative 
feedback loop mediated through ERK1/2. When p-ERK1/2 levels decrease, the relief 
of the feedback loop allows stronger activation of upstream components and 
ultimately reactivates phosphorylated MEK1/2 levels.  
Moreover, we evaluated the effects of the treatments on the levels of p-CRAF 
S259, a site previously reported to be an inhibitory phosphorylation mediated directly 
by AKT (49, 54, 55). Our hypothesis was that the compensatory activation of p-
MEK1/2 following RICTOR knockdown is mediated through de-repression of the 
inhibitory CRAF phosphorylation as a result of decreased activation of AKT, leading to 
a more active CRAF involved in transduction of mutant KRAS signaling (Figure 21A). 
A proposed model of this interaction is illustrated in Figure 21C. Densitometric 
quantification of p-CRAF shows that siRICTOR decreased p-CRAF S259 by an 
average of 34% compared to parental and NTC H23 cells (Figure 21B). Conversely, 
the specific mTORC1 inhibitor, everolimus, did not yield a significant reduction, likely 
due to the hyperactivation of p-AKT; however, the combination of everolimus with 
siRICTOR had an average 43% reduction of p-CRAF S259, similar to siRICTOR 
alone. Interestingly, treatment with the dual mTORC1/2 inhibitor, AZD2014, only 
decreased the p-CRAF levels by an average of 23%. This could suggest that RICTOR 
may have a more important interplay with AKT, independent of its interaction with 
mTORC2, in modulating AKT activity and ultimately regulating CRAF activation 
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through mutant KRAS. Alternatively, the lower reduction of p-CRAF seen by AZD2014 
could be due to the specificity of AZD2014’s inhibitory mechanism on the mTOR 
kinase directly, and not RICTOR, suggesting that there is a unique and specific 
interplay between RICTOR and KRAS/CRAF. This also brings forward the idea of 
developing a specific RICTOR inhibitor.  
Additionally, in comparing the various targeted drugs and their effects on cell 
viability, apoptosis was measured via the detection of cleaved PARP levels (Cl-PARP) 
across the panel of drug treatments. In concordance with our proposed hypothesis 
that a dual pathway inhibition strategy targeting both, the mTOR and MAPK 
pathways, is an effective solution in RICTOR/KRAS-altered molecular settings, our 
results here show that the greatest apoptotic induction is seen when using AZD2014 
in combination with AZD6244 (Figure 21A). When RICTOR alone is knocked down, 
we do not see significant upregulation of cleaved PARP even though p-AKT levels 
decrease, suggesting that the compensatory activation of the MAPK pathway, through 
upregulated p-MEK1/2, is allowing the cells to sustain viability by promoting alternate 
survival mechanisms, as evidenced in section 5.3 below.  
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Figure 21. Compensatory MEK1/2 activation following RICTOR knockdown 
may be mediated through de-repression of inhibitory CRAF phosphorylation. 
(A) H23 cells were treated with the indicated siRNAs for a total of 72 hours and 
compounds were administered for 24 hours (all at 1µM, except AZD6244 at 5µM) 
before cells were harvested. Western blot analyses was performed and 
densitometric quantification done using Image Studio Lite 5.0 software and bands 
were normalized to the respective β-Actin control bands. (B) Percent inhibition of p-
CRAF S259 plotted per sample relative to the average of Parental and NTC 
samples. (C) Model illustrating the proposed mechanism of p-MEK1/2 activation 
following RICTOR knockdown in KRAS mutant cells. 
A B 
C 
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5.3 Human p-MAPK array reveals RICTOR knockdown affects the activity of 
several mediators of cellular stress and survival pathways. 
 We next subjected our RICTOR amplified, KRAS mutant cell line, H23, to a 
human p-MAPK array which allows us to monitor the phosphorylation levels of 26 
kinases. We treated H23 cells with NTC or siRICTOR for 72 hours, and following 
whole-cell lysis, incubated the lysates with the phosphorylation specific array. Figure 
22A shows differences of band intensities (in duplicates) for 26 different kinases 
involved in the major MAPK pathways. Western blotting was performed separately on 
the NTC and siRICTOR lysates to confirm effective RICTOR knockdown (Figure 22B). 
Only kinases that were differentially activated (phosphorylated) were marked with 
corresponding numbers and ultimately quantified to evaluate difference in activity 
(Figure 22C). Densitometric quantification found several MAPK-related kinases that 
were downregulated following RICTOR knockdown. Notably, we found decrease in 
phosphorylation levels of CREB (S133), HSP27 (S78/82), and p38a (T180/Y182). 
Interestingly, these MAPK pathway effectors are found to play broad roles as key 
mediators of cellular stress response, survival, and proliferation (47, 134-136). These 
results open several possible mechanisms by which RICTOR, either through an 
mTORC2-dependent or independent process, is able to contribute to the oncogenic 
properties of NSCLC revealed by our work, by mediating the MAPK pathway(s). 
Future experiments are still needed to fully decipher these potential mechanisms.  
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Figure 22. Human p-MAPK array reveals RICTOR is linked to several 
mediators of cellular stress and survival. (A) Whole-cell extracts from H23 cells, 
treated with a NTC or siRICTOR for 72 hours, were incubated with the Human p-
MAPK array, and phosphorylation status of 26 kinases was captured from a 5 
minute exposure to X-ray film. (B) Western blotting analysis of lysates used for 
array shows knockdown efficiency of siRICTOR. (C) Densitometric quantification of 
selected phospho-kinases (in duplicates) marked by corresponding numbers. 
A B 
C 
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Chapter 6 
Results 
6.1 RICTOR knockdown enhances the pharmacologic efficacy of MAPK pathway 
inhibition in RICTOR/KRAS-altered NSCLC cell lines 
To exploit the compensatory MAPK pathway activation seen following RICTOR 
signaling inhibition, we evaluated the effect of blocking the MEK-ERK signaling 
pathway via pharmacologic agents alone or in combination with genetic RICTOR 
blockade, in specific KRAS co-mutational settings in vitro. We tested two currently 
available allosteric MEK1/2 inhibitors, selumetinib (AZD6244) and trametinib 
(GSK1120212), either alone or in combination with shRICTOR treatment in three 
RICTOR amplified, KRAS mutant shRICTOR inducible cell lines via MTT assay 
(Figure 23A). Pharmacologic disruption of signaling in the MEK-ERK pathway by 
selumetinib (5 µM) or trametinib (0.05 µM) alone rendered all three cell lines resistant 
(> 50% viability) at the selected doses. However, the response was more marked in 
the presence of shRICTOR in combination with MEK1/2 targeted therapy, seen by a 
significant reduction in cell viability compared to either inhibitor alone (P < 0.0001). 
We next checked the signaling effects induced by the MEK1/2 inhibitors with or 
without RICTOR knockdown by Western blotting analysis in the representative H23 
cell line (Figure 23B). Single treatment with either MEK inhibitors or combined with 
shRICTOR suppressed AKT and MAPK signaling pathways (seen by reduced p-AKT 
and p-ERK levels, respectively) in a dose-dependent manner. In concordance with the 
aforementioned cell viability results, there was a substantial increase in the cleaved 
PARP (cl-PARP) levels detected in samples treated with concomitant MEK inhibitors 
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and shRICTOR compared to MEK inhibition alone, signifying reduced cell viability as 
a result of increased apoptosis.  
 
  
A 
B 
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Figure 23. RICTOR knockdown enhances the pharmacologic efficacy of 
MAPK pathway inhibition in RICTOR/KRAS-altered NSCLC cell lines.  
(A) Inducible shRICTOR NSCLC cell lines were cultured in the presence or 
absence of 2μg/mL doxycycline to induce shRICTOR knockdown, alone or in 
combination with either selumetinib (AZD6244, 5μM) or trametinib (0.05μM). After 
7 to 10 days of treatment, cell viability was measured by MTT assay and compared 
between shRICTOR alone and in combination with MEK1/2 inhibitors. Separate 
wells were stained with crystal violet on the same day to visualize and complement 
cell viability data. Data are graphed as the mean percentage ± percent SD. ***, P < 
0.0001. 
(B) Western blot analysis of inducible H23 cell line treated with increased doses of 
selumetinib (left, 1, 5, 10 μM) or trametinib (right, 5, 10, 100 nM) alone or in 
combination with 2μg/mL doxycycline to induce shRICTOR knockdown for a total 6 
days. Total and phospho-specific antibodies used were for levels of RICTOR, p-
AKT (S473), AKT, p-ERK1/2 (T202/Y204), ERK1/2, cleaved-PARP, PARP, and β-
Actin as loading control. 
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6.2 Combined mTORC1/2 and MEK inhibition is an effective therapeutic 
approach in RICTOR/KRAS-altered settings and results in synergistic anti-
tumor effects in vitro 
We next wanted to investigate the efficacy of our dual pathway inhibition 
approach by use of two currently available pharmacologic inhibitors either alone or in 
combination across several RICTOR amplified or non-amplified NSCLC cell lines that 
carry various secondary mutations in the PI3K/AKT/mTOR and/or MAPK pathways. 
We performed an MTT assay after treating cells with selumetinib and/or the dual 
catalytic mTORC1/2 inhibitor AZD2014 (currently in phase II clinical trials) at the 
specified doses (Figure 24). In H23, H2009, and H1792 (RICTOR amplified, KRAS 
mutant) cell lines, concomitant targeting of mTORC1/2 and MEK resulted in 
approximately 75% reduction of cell viability in all three cell types. Of note, H23 also 
harbors LKB1 and PTEN mutations, which could explain why this cell line is more 
resistant to either single agent treatment when compared to H2009 or H1792. We 
then tested our inhibitors in two RICTOR non-amplified cell lines, HCC44 and 
HCC193, which are KRAS mutant or wild-type, respectively. In HCC44 cells, 
combined selumetinib and AZD2014 treatment decreased cell viability by over 75%; 
however, HCC193 cell lines were relatively resistant to either agent alone or the 
combination (> 50% cell viability). To further confirm that this dual pathway inhibition 
is most effective specifically in KRAS co-mutant settings, we used the isogenic human 
bronchial epithelial cell lines (HBECs) previously described (137, 138), that either 
have KRAS wild-type (HBEC3-KT) or KRAS G12C mutation (HBEC3-KT-G12C). Our 
results indicated that in concordance with the aforementioned data in NSCLC cell 
lines, HBEC3-KT cells with KRAS mutation are significantly more sensitive to the dual 
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pathway blockade of selumetinib with AZD2014 (~75% reduction in cell viability) 
compared to the KRAS wild-type cells which were more resistant (~50% viability).  
In addition, we assessed whether the combination therapy of both drugs 
resulted in synergistic, additive, or antagonistic effects across a range of therapeutic 
doses by MTS assay. H23, H2009, H1792 (RICTOR amplified, KRAS mutant) cell 
lines were treated with various concentrations of AZD2014 (0.024-12.5μM) and a 
fixed set of selumetinib doses (2.3, 4.6, 9.3, or 18.7μM) for 96 hours (Figure 25). We 
calculated the combination index (CI) values based on the previously described Chou-
Talalay model (139) using ComboSyn software (ComboSyn Inc, Paramus, NJ). The 
CI parameters used were: CI = 0-0.9, synergism; CI = 0.9-1.1, additive effect; CI > 
1.1, antagonism. In all three representative cell lines, optimal drug dose combinations 
that impose synergistic effects were found. H23 showed the highest level of 
synergism in the range of AZD2014 (0.024-0.781μM) combined with selumetinib (2.3 
or 4.6 μM), whereas increasing the AZD2014 and/or selumetinib combination doses 
outside of these ranges resulted in a loss of synergy and caused an additive or 
antagonistic effect. In H2009, we found consistent synergism across most of the 
combination dose ranges used, and in H1792 the synergistic and/or additive effects 
were observed in the range of AZD2014 (0.195-6.25μM) combined with selumetinib 
(2.3-18.7μM). Collectively, these findings suggest that a dual pathway inhibition 
approach is warranted in specific NSCLC settings where RICTOR/KRAS alterations 
exist, and that careful consideration should be given when combination dosing is 
performed to render most effective synergistic anti-tumor effects.  
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Figure 24. Combined mTORC1/2 and MEK1/2 inhibition is an effective 
therapeutic approach in RICTOR/KRAS-altered in vitro settings.  
Five NSCLC cell lines (3 RICTOR amplified (red), 2 RICTOR-non-amplified 
(blue)) and two immortalized human bronchial epithelial cell lines (HBECs, black) 
were treated with DMSO (control), selumetinib (1 μM), AZD2014 (0.1 μM), or the 
combination selumetinib (1 μM) with AZD2014 (0.1 μM). Mutation status of 
KRAS, LKB1, PTEN, and EGFR are shown below each cell line. After 72 hours 
of treatment, cell viability was compared to control DMSO cells and measured by 
MTT assay. Data are graphed as the mean percentage ± percent SD. **, P < 
0.01; ***, P < 0.0001.  
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Figure 25. AZD2014 and selumetinib act synergistically to block mTOR and 
MAPK pathway signaling in vitro.  
Three NSCLC (RICTOR amplified, KRAS mutant) cell lines were incubated with 
increasing concentrations of AZD2014 (0.024-12.5μM) and a fixed dose of 
selumetinib (0, 2.3, 4.6, 9.3, 18.7 μM) for 96 hours. Controls were treated with 
DMSO only. Cell viability was analyzed by MTS assay. Data are graphed as the 
mean percentage ± percent SD. Combination index (CI) values were calculated 
using ComboSyn software (ComboSyn Inc, Paramus, NJ). The CI parameters 
used were: CI = 0-0.9, synergism; CI = 0.9-1.1, additive effect; CI > 1.1, 
antagonism. 
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6.3 Comparative effects of mTORC1/2 and MEK1/2 pathway inhibition in vivo 
 To determine whether the synergistic effects seen in vitro translated into anti-
tumorigenic effects in vivo, we utilized our stably transduced inducible shRICTOR cell 
line H1792 (RICTOR amplified, KRAS mutant) to subcutaneously establish tumor 
xenografts in mice. Once tumors reached a palpable size of 150 to 200 mm3, the 
animals were randomized into five treatment arms: vehicle (1% tween-80, bid), 
selumetinib (25mg/kg, bid), selumetinib (25mg/kg, bid) + doxycycline feed 
(600mg/kg), AZD2014 (15mg/kg, qd), and selumetinib + AZD2014 (equivalent 
dosages used as per individual inhibitor treatments). Dose administration via oral 
gavage was performed for a total of 22 days continuously, with tumor volumes and 
mouse body weights recorded twice weekly (Figure 26 A, B). 
 Results show that in comparison to the vehicle (control) group, mice receiving 
selumetinib with AZD2014 had the most enhanced antitumor effects compared to 
single-agent treatment groups. Similarly, we saw a significant reduction of tumor 
growth in the selumetinib with shRICTOR (+Doxy) treatment arm compared to control, 
although the utilization of the abovementioned combination drugs still had a more 
pronounced reduction in tumor volume. Interestingly, in concordance with our in vitro 
H1792 cell viability MTT data (Figure 24), selumetinib treatment alone resulted in an 
increased reduction of cell viability/tumor growth compared to single agent AZD2014 
treatment, suggesting that this particular KRAS mutant setting (KRASG12C) is more 
sensitive to MEK1/2 inhibition than mTORC1/2, despite having amplification of 
RICTOR present. Furthermore, to determine whether these effects were seen without 
detrimental consequences on the health and well-being of the experimented animals, 
body weight of animals was measured several times a week (Figure 26B). No 
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significant loss of body weight or visible signs of declined health were witnessed 
during the duration of any of the treatments. 
 Following the last treatment dose, tumors were extracted after 3 hours 
proceeding the final dose administration, and tumor lysates were prepared as 
described in materials and methods section. Representative samples from each 
treatment arm were subject to Western blotting analysis (Figure 26C). Results 
revealed that the treatments alone and the combination inhibited their direct targets of 
each inhibitor. The treatment groups incorporating selumetinib effectively blocked 
downstream p-ERK1/2 signaling, AZD2014 had a marked reduction in the 
downstream mTORC1/2 effectors p-AKT, p-S6RP and p-4EBP1, and shRICTOR 
induction with doxycycline showed a reduction in the total RICTOR protein levels. 
Collectively, these findings suggest that AZD2014 in combination with selumetinib 
result in significant anti-tumor effects mediated through mTORC1/2 and MEK dual 
pathway inhibition, and is an effective therapeutic strategy in RICTOR/KRAS-altered 
NSCLC. 
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Figure 26. Selumetinib in combination with shRICTOR or AZD2014 results 
in the strongest anti-tumor activity in vivo. 
(A) Athymic nude mice were inoculated subcutaneously with the inducible H1792 
shRICTOR cell line. Once tumor volumes reached an average of 150 to 200 
mm3, mice were randomized to each treatment group and given the respective 
treatments via oral gavage daily for a total of 22 days. Tumor volumes were 
measured twice weekly, and data points are presented as the mean tumor 
volume ± SEM. Colored asterisks represent significant difference of that 
treatment from a different treatment resembled by its respective line color. (*, P < 
0.05; +, P < 0.01). (B) Average body weight of mice is displayed for each 
treatment arm, and measured twice weekly. (C) Western blot analysis showing 
the levels of indicated proteins in tumor lysates harvested 3 hours after last drug 
treatment on day 22. 
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Chapter 7 
Discussion, Conclusions, and Future Directions 
 Lung cancer is the leading cause of cancer-related mortality worldwide, with a 
dismal five year survival of less than 16% and over 1.5 million deaths annually (140). 
Despite improvement in early detection strategies and standard treatment options, it 
continues to have a poor prognosis. What were once considered a single disease 
entity, lung tumors are now comprised of discrete genetically and clinically distinct 
subtypes. NSCLC is the most prevalent type of lung cancer, and the last decade has 
seen significant effort invested in the advent of rapid genomic profiling that led to 
development of molecular-targeted therapy that inhibit key oncogenic drivers such as 
EGFR, ALK, and RAF, resulting in dramatic responses in patients (5). However, even 
though responses are seen initially, these targeting agents rarely promote complete or 
durable antitumor effects especially in unselected patients, leading to acquired 
resistance mechanisms and relapse. Further, effective therapeutic options still lack for 
lung tumors driven by other key mutations such as in oncogenic KRAS (~30%) and 
those with untargetable oncogenic drivers that are yet to be discovered (123, 141). 
Moreover, it is now evident more than ever that clinical trials performed in the 
absence of sufficient molecular and genetic stratification lead to poor response rates 
in patients.  
In this study, we aimed to identify novel actionable genetic alterations in lung 
cancer by utilizing genomic profiling data from the BATTLE-2 clinical trial that targets 
advanced stage chemorefractory NSCLC patients. We identified RICTOR alterations 
(amplifications and/or mutations) to be present in 17.4% (16/92) of advanced stage 
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NSCLC patients, including 11.9% amplifications (11/92) and 5.4% mutations (5/92). 
Mutations in the RICTOR gene have not been previously characterized, and thus the 
precise functional significance of these mutations is yet to be determined. To date, 
only one correlative study was found from literature searches highlighting a specific 
RICTOR polymorphism (rs6878291) associated to clinical benefit and that serves as 
an independent risk factor for progression-free survival in a cohort of Chinese NSCLC 
patients treated with platinum-based chemotherapy (142) . However, the exact 
functional significance of this SNP is unknown and further validation is needed in an 
independent cohort to draw any major conclusions from this study. Interestingly, 
mutations in the RICTOR gene identified from the BATTLE-2 patients were all 
mutually exclusive from RICTOR gene amplifications. We also surveyed early-stage 
lung adenocarcinoma cases using the TCGA dataset, and identified a total 13.4% 
(31/230) of RICTOR-altered cases, which included 10% amplifications (23/230) and 
5.2% mutations (12/230). When we utilized the cBioPortal dataset analysis tool to 
identify the frequency of RICTOR alterations across numerous different tumor types, 
we found that alterations in this gene are also found in other cancers and are not 
exclusive to lung tumors. However, the highest frequency of alterations was found in 
NSCLC, particularly in lung adenocarcinoma. Further, in contrast to our advanced 
stage BATTLE-2 cases, we identified 4 early stage cases in the TCGA dataset that 
had concomitant RICTOR gene amplifications and mutations. These data might 
suggest that advanced-stage tumors do not require concomitant alterations in the 
RICTOR gene to drive the involved pro-tumorigenic processes, whereas some early 
stage tumors require concomitant mutations. Also, it is not clear which alteration 
type—RICTOR amplification or mutation—is more important in the oncogenic process 
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or in terms of response to specific targeted therapies. An example of the importance 
of this difference was shown in a report analyzing mutations versus amplifications of 
the gene, KIT, in melanomas, and found that patients with KIT mutations had 
responses to the tyrosine kinase inhibitor, imatinib, whereas those with amplifications 
had no response (143). As noted above, a closer examination of the functional 
significance of these mutations is required to fully decipher their implications in 
NSCLC tumorigenesis. Experimental approaches such as site-directed mutagenesis 
or targeted CRISPR-Cas9 approaches in vitro can be utilized to aid in such studies. 
Gene amplifications refer to the increase in copy number levels of a gene 
within the genomic DNA of a cell. Amplification of a gene typically involves the 
overexpression of the gene product, consequently leading to selective advantages for 
tumor cell growth. We were interested to evaluate the correlation between RICTOR 
amplification and RICTOR gene expression in our two datasets. Our findings show 
that there was a significant direct correlation between RICTOR gene amplification and 
RICTOR mRNA expression in the early stage TCGA dataset, and a trend seen in the 
advanced stage BATTLE-2 lung adenocarcinoma cases. It is important to note that 
when we performed this analysis including all NSCLC subtypes from the BATTLE-2 
cases (total of 159 cases that were subjected to DNA NGS profiling), there was 
statistical significance of direct correlation between RICTOR gene amplification and 
RICTOR mRNA expression (data not shown). These differences in significance could 
be due to either the smaller sample size of RICTOR amplified lung adenocarcinoma 
cases being a limitation factor, or that in other NSCLC subtypes (e.g. small-cell lung 
carcinomas), increased RICTOR copy number levels definitively drive the mRNA 
expression of RICTOR in those tumor histotypes. Another possibility could be 
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differences in epigenetic and micro-RNA (miRNA) regulatory mechanisms in these 
tumors. One such example is a study that found that DNA hypermethylation silences 
miR-218 in oral squamous cell carcinoma, which directly targets RICTOR and 
suppresses its expression and activity (112). Another study showed that the 
downregulation of miR-153 resulted in increased RICTOR mRNA and protein 
expression and tumorigenic activity, explaining the upregulation of RICTOR seen in 
human glioma tissues and cell lines (144). 
We next wanted to determine the association of RICTOR alterations to 
prognosis using our clinical datasets. Since we have mutation data from our BATTLE-
2 and TCGA datasets, we checked whether there is association between 
dichotomizing RICTOR amplified, mutated, or altered (combining amplified/mutated) 
cases versus non-altered cases, and correlated these parameters to overall survival 
and progression-free survival (data not shown). Results yielded a lack of statistical 
significance between all these analyses, most likely due to inadequate statistical 
power as a result from the limited number of mutant cases. Since we found an overall 
direct correlation between RICTOR amplification and mRNA expression, we next 
analyzed whether levels of RICTOR mRNA expression associated to outcome in our 
datasets. For this analysis, in addition to our BATTLE-2 (advanced stage) and TCGA 
(early stage) cases, we utilized the PROSPECT cases, a dataset our laboratory 
possesses, which is comprised of early stage surgically resected lung 
adenocarcinoma tumors, in which we have mRNA expression and clinical outcome 
data. We performed a univariate overall survival analysis of RICTOR mRNA 
expression using the Cox proportional hazards model. We found a significantly worse 
overall survival in patients with advanced stage lung adenocarcinoma in the BATTLE-
90 
 
2 cases. We also noted poor prognosis in our early stage surgically resected lung 
adenocarcinoma cases from the PROSPECT dataset; however, no significance was 
seen in patients from the TCGA dataset. One possible explanation could be that in 
heavily pre-treated advanced stage cases (BATTLE-2), RICTOR serves a more 
dominant role in driving malignant phenotypes of tumors and has an important 
interplay with co-oncogenes such as KRAS, ultimately leading to a worse survival of 
patients due to the severity of mutational burden. Similarly, although the PROSPECT 
cases are still considered early stage cases relative to the BATTLE-2 cohort, these 
tumors are more advanced compared to the TCGA lung adenocarcinomas. On the 
contrary, in the TCGA cases, the mutational load is lower due to the early stage and 
less treatment exposure, and therefore RICTOR serves more as a secondary driver 
and requires, in some cases, to harbor concomitant mutations and amplifications in 
RICTOR to perhaps drive cancer progression. Although the true prognostic 
implications of RICTOR remain unclear in the context of NSCLC, a more expanded 
analysis of larger study cohorts may provide more conclusive information on 
RICTOR’s predictive and prognostic role. To date, RICTOR’s association with 
prognosis has been proposed in some tumor types with differing conclusions. For 
instance, RICTOR mRNA and protein expression was determined to be an 
independent prognostic factor for endometrial carcinoma (145). Also, RICTOR mRNA 
expression was identified as an independent prognostic indicator for disease-free 
survival in patients with hepatocellular carcinoma (146). Conversely, elevated 
RICTOR mRNA expression was found in normal breast tissues, lower tumor grade, 
and correlated with a significantly better disease-free and overall survival (147). 
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A recent study by Cheng et al. highlighted RICTOR amplification as a distinct 
subset of lung cancer patients, and reported RICTOR amplifications in 8.4% of lung 
adenocarcinomas from an independent cohort (Foundation Medicine, Inc.) (117). Of 
these, 11% of the cases harbored RICTOR amplification as the sole potentially 
actionable target out of a targeted gene panel. In concordance with our data, the 
study highlighted the oncogenic role of RICTOR by showing that RICTOR inhibition 
resulted in reduced cancer cell growth and cell survival in NSCLC cells amplified for 
RICTOR. Moreover, their data indicated that dual mTORC1/2 inhibition was effective 
against RICTOR amplified lung cancer cells. They further reported one patient 
(harboring RICTOR amplification as the single actionable genomic alteration found) 
that underwent treatment with dual mTORC1/2 therapy, and had over 18 months of 
tumor stabilization. Although the strategy of dual mTORC1/2 therapy for RICTOR 
amplified cases seems reasonable in settings where the only major oncogenic 
actionable driver is RICTOR, our data presented here suggest that this treatment 
strategy may not be as effective in lung tumors where other genomic aberrations are 
present.  
To gain insight into the co-mutational landscape that exists in RICTOR-altered 
cases, we utilized the cBioPortal platform to survey the TCGA dataset for enrichment 
of specific pathway alterations that are known to be deregulated in lung cancers. We 
examined the frequency of alterations (mutations and/or copy number changes) in 
genes known to mediate key pathways, including tyrosine kinase (RTK) signaling, 
mTOR signaling, MAPK signaling, and oxidative stress response. Of great interest, 
we found co-mutational enrichment of alterations in genes involved in the oncogenic 
MAPK pathway, including KRAS, NF1, BRAF, and CRAF. The elevated frequency of 
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these co-mutations suggested that RICTOR could potentially serve as an important 
co-oncogenic driver in lung cancer progression in specific molecular settings. KRAS 
has been an orphan target, and numerous attempts in its direct and even indirect 
targeting have failed (88). Therefore, a great shift in focus over the years has 
occurred to study and potentially inhibit downstream or parallel effector pathways and 
molecules. Additionally, characterizing the genomic landscape of KRAS mutant lung 
tumors is critical to better determine co-driver alterations that when identified and 
appropriately targeted, can re-sensitive RAS-driven tumors to the given therapeutic 
modalities. These results tailored our experimental efforts and focus on characterizing 
the significance of RICTOR in the context of NSCLC, specifically in a KRAS co-
mutational setting 
Our in vitro cell line models were carefully selected to reflect the heterogeneity 
of NSCLC and specific mutations in the MAPK pathway. Cell lines selected were 
either RICTOR amplified or non-amplified, and included various co-mutations in 
KRAS, PTEN, PIK3CA, STK11, and/or EGFR. Similar to our clinical findings that 
RICTOR amplified cases directly correlated with RICTOR mRNA expression, we 
found that our RICTOR amplified cell lines had a significantly higher RICTOR protein 
expression compared to non-amplified cell lines. This is supportive of the idea that 
amplification of this gene drives the overexpression of the protein product, perhaps 
leading to increased malignant effects. 
Since RICTOR’s roles in tumorigenesis are actively emerging, both dependent 
and independent of the mTORC2 complex, we sought to characterize the phenotypic 
consequences of modulating the levels of RICTOR in our in vitro cell line panel to 
better understand RICTOR in the context of NSCLC. We found that RICTOR 
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knockdown significantly reduces the clonogenic and anchorage-independent growth 
of RICTOR amplified cells. In assessing its role on the tumorigenic potential in a more 
physiologically relevant in vivo settings, we found that knocking down RICTOR in 
H1792 and H23 (RICTOR amplified, KRAS mutant) xenografts significantly abrogated 
the tumorigenicity of these cells in nude mice. These results are in concordance with 
other studies showing that in various tumor types, including gliomas, bladder, ovarian, 
and prostate cancers, RICTOR contributes oncogenic properties (103, 117, 148, 149). 
Moreover, when we performed migration and invasion assays, we found that 
RICTOR knockdown in RICTOR amplified cell lines significantly abrogated the 
migrative and invasive capacity of these cells. RICTOR’s role in migration and/or 
invasion has been previously reported. For example, several reports have shown that 
in glioma and bladder cancer cell lines, the genetic silencing of RICTOR significantly 
reduced cell growth, migration and invasion (103, 148). In addition, Lamouille et al. 
have shown that the mTORC2 complex is an essential downstream mediator of TGF-
β signaling, affecting cellular migration (through regulation of focal adhesions in 
response to paxillin expression), invasion (through induction of MMP9 expression), 
and cancer cell dissemination (through EMT-associated cytoskeletal and gene 
expression changes) (150). Moreover, the RICTOR/mTOR complex has been 
reported to modulate the activity of PKCα in regulating the actin cytoskeleton to impair 
cell motility (41); however, this mechanism could be cell type specific, as another 
study was unable to determine similar findings upon treatment with classic PKC 
inhibitors to reverse this phenotype (151). Instead, their findings suggested that 
RICTOR interacts and specifically regulates PKCζ activation to induce cancer cell 
metastasis in an mTORC2-independent manner (151). On the contrary, Das et al. 
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reported that suppression of RICTOR actually resulted in an increased invasive 
capacity of glioma cells by enhancing the expression of MMP9 through a RAF1-MEK-
ERK mediated pathway (152). Perhaps one of the more convincing pieces of 
evidence shedding light on RICTOR’s independent role on regulating cell migration 
was elucidated in a study showing that loss of RICTOR leads to the induction of 
RhoGDI2, which disrupts cell migration via the inhibition of RAC1 and CDC42 
GTPase activity (106). Both of these GTPases have been shown to regulate cell 
motility and the actin cytoskeleton (153). Interestingly, in our studies, the trend of 
downregulation of cell migration and invasion following RICTOR abrogation was 
observed specifically in RICTOR amplified cell lines that also carried concomitant 
KRAS mutations (H23, H2009, and H1792). We did not observe this trend in RICTOR 
amplified but KRAS wildtype cell lines (H2172, H2126). KRAS has been previously 
linked to regulating migration and invasion in various cancer types. Specifically, 
mutant KRAS has been shown to promote invasion and metastasis in pancreatic 
cancer through regulation of GTPase pathways involving RhoGAP5, RalA, and CAV-1 
(154). Additionally, Sunaga et al. showed that oncogenic KRAS in NSCLC induces 
interleukin-8 overexpression to promote cell migration (155). Although the mechanism 
underlying the role of RICTOR, specifically in the context of mutant KRAS, in 
regulating migration and invasion was outside of the scope of this project, it would be 
interesting to show which, if any, of these previously reported mechanisms occur in 
our cell types, and whether mutant KRAS has a direct involvement in mediating these 
phenotypes in our cell types. 
Furthermore, to better understand the phenotypic consequences described 
thus far, we wanted to evaluate if RICTOR affects cell proliferation. From our 
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experimental results, we found that silencing RICTOR in our amplified cell lines 
resulted in a significant reduction in cell number over time. Also, we found that there 
was a slight increase in G0/G1 cell cycle arrest as seen in our FACS cell cycle 
experiments. Western blotting analysis further confirmed that there was a decrease of 
cyclin D1 levels following RICTOR knockdown in the H23 cell line tested. Other 
studies have linked the regulatory effects of RICTOR/mTORC2 to cell cycle 
progression. For instance, depletion of RICTOR resulted in increased G1 phase arrest 
caused by downregulation of cyclin D1, resulting in reduced proliferation and 
anchorage-independent growth in pancreatic and breast cancer cell lines (115). In 
agreement, a similar link was described in melanoma cells overexpressed with 
RICTOR which led to increased proliferation, colony formation, and cyclin D1 
expression (127). Similarly, in hepatocellular carcinoma cells, targeted inhibition of 
RICTOR, but not RAPTOR, promoted G0/G1 cell cycle arrest and was explained by 
the reduced phosphorylation of p-AKT S473 levels, suggesting that hydrophobic motif 
phosphorylation of AKT may be required for the maintenance of cyclin D1 expression 
(129). There could be various mechanisms by which RICTOR’s effects on cell cycle 
progression are mediated. One mechanistic basis of the reduction of cyclin D1 was 
shown in a study that pinpointed to the inhibition of mTORC2 triggering a proteasome-
mediated cyclin D1 degradation via a GSK3-dependent manner, and suggested that 
specifically RICTOR, as part of mTORC2, is responsible for increasing the stability of 
cyclin D1 (128). This study further highlighted that although AKT is known to positively 
regulate cyclin D1 stability through the negative phosphorylation and inactivation of 
GSK3 (156), the reduced levels of cyclin D1 are independent of AKT. Other studies 
have reported that mTORC2 targeting suppresses cyclin D1 translation by inhibiting 
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the recruitment of cyclin D1 mRNA to polysomes in certain leukemia cells (157, 158), 
since the downstream AKT/mTORC1 translational repressor, 4E-BP1, is known to be 
involved in the regulation of cap-dependent mRNA translation and can also be 
deactivated upon mTORC2 inhibition (29, 159). However, further investigation is 
needed to precisely decipher the relationship between RICTOR/mTORC2, AKT, and 
4E-BP1 in cell cycle progression. 
The consequences of RICTOR inhibition from our studies clearly highlighted 
the significance of this oncogene in the context of NSCLC. We next wanted to 
characterize the cell signaling patterns associated with RICTOR in our cell line panel. 
Our findings demonstrated that exclusively in KRAS co-mutational backgrounds, 
knockdown of RICTOR resulted in a compensatory increased activation of 
phosphorylated MEK1/2 levels compared to controls. We further discovered that this 
compensation occurs in both RICTOR amplified and non-amplified settings, 
suggesting that regardless of the increased expression of RICTOR in amplified cells, 
there is an important interplay between RICTOR and mutant KRAS in mediating 
crosstalk mechanisms between the mTOR/AKT and RAS/MEK pathways. Our in vitro 
work further uncovered that when we perform concomitant knockdown of RICTOR 
and KRAS, there is no increase in p-MEK levels, suggesting that mutant KRAS is 
required for this compensatory mechanism to occur.  
To further define a potential mechanism mediating this crosstalk between these 
two parallel oncogenic pathways, we tested the hypothesis that the compensatory 
activation of p-MEK1/2 following RICTOR blockade is mediated through the de-
repression of the inhibitory CRAF S259 phosphorylation as a result of decreased 
activation of AKT, leading to a more active CRAF involved in transduction of mutant 
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KRAS signaling. Previous reports have identified this negative crosstalk mechanism 
between AKT and CRAF in certain cellular contexts (49, 54, 55). In our tested H23 
cell line, we found that genetic inhibition of RICTOR decreased p-AKT levels and as a 
result, reduced the phosphorylation of CRAF S259, suggestive of increased CRAF 
activity. When we tested the mTORC1 inhibitor everolimus, we did not find a 
significant reduction in the phosphorylation levels of CRAF, in line with the displayed 
elevated p-AKT levels, and in agreement with previously described AKT feedback 
loops following mTORC1 inhibition (130, 131). When we combined siRICTOR in 
combination with everolimus, there was a similar reduction of p-CRAF S259 levels as 
siRICTOR alone, displaying the lack of mTORC1 contribution to this crosstalk 
mechanism. Interestingly, treatment with our dual mTORC1/2 inhibitor, AZD2014, had 
only a slight effect on decreasing the inhibitory p-CRAF levels, despite having a 
pronounced reduction in p-AKT levels. These data suggest that RICTOR may have a 
unique interplay with AKT in mediating the CRAF cross-talk activity, independent of 
mTORC1 and mTORC2. Similar to our finding, a study by Das et al. showed that 
RICTOR ablation enhanced the phosphorylation of MEK, ERK, and also increased the 
CRAF kinase activity in glioma cells (152). In further support of the preliminary 
evidence shown here, there have been several reports signifying the importance of 
CRAF in the context of mutant KRAS. For example, in KRAS-driven NSCLC, CRAF, 
rather than BRAF, was determined to be the critical effector in mediating KRAS 
signaling (160). Similarly, Karreth et al. has shown that KRASG12D mutations elicit their 
oncogenic effects primarily through CRAF in a lung cancer mouse model, whereas 
BRAF is dispensable (161). Voice et al. has shown that of all the human RAS 
homologs tested, KRAS was revealed to be the most significant activator of CRAF in 
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vivo (162). In line with this, Lito et al. showed convincing evidence that in KRAS 
mutant tumors, effective MEK inhibition (and essentially MAPK pathway 
downregulation) requires the disruption of CRAF mediated MEK activation (163). 
Taken together, although our preliminary mechanistic findings here suggest a 
possible link between RICTOR/AKT-mediated regulations of CRAF activity in a KRAS 
mutant setting, further investigation is warranted. For example, it would be interesting 
to study the effects of genetic or targeted inhibition of AKT in this setting to 
conclusively confirm this negative crosstalk. Furthermore, it would be important to 
perform immunoprecipitation experiments to see if RICTOR, AKT, and/or CRAF 
directly bind in this particular cell line, and whether other mTORC2 components are 
involved. This will elucidate whether RICTOR is acting upon AKT independently of 
mTORC2 in this cell type, as prior studies have shown this to be a possibility (108, 
109). Lastly, since this experiment was performed in one cell line (H23, RICTOR 
amplified, KRAS/STK11/PTEN mutant), it would be imperative to expand this study in 
other cell lines, particularly those that do not possess RICTOR amplification and/or 
the other listed co-mutations. This would shed light as to which specific genomic 
landscape the crosstalk occurs in, as it is well established that the complex 
heterogeneity of even cell lines results in differential signaling mechanisms.  
As we continued to explore the cell signaling effects mediated by RICTOR in 
our RICTOR amplified cell lines, we performed a phospho-MAPK proteomic array on 
our H23 cell line to compare siRICTOR versus control cells. We found that RICTOR 
inhibition decreased the phosphorylation and activation levels of p38α, CREB, and 
HSP27. Interestingly, these kinases have broad roles in mediating cellular stress 
response, survival, and/or proliferation, in which some of the signaling pathways and 
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functionalities overlap, especially since these kinases can, in fact, regulate one 
another (47, 134). Notably, the most significant difference in phosphorylation was 
seen in p38α, which has been reported to have both tumor suppressive and 
oncogenic roles, depending on the cellular context. Although some reports have 
shown prosurvival functionalities, many others have associated this kinase with the 
induction of apoptosis during cellular stress (47). Another report confirmed similar 
results as ours, showing that in mice in which RICTOR is conditionally knocked out in 
the liver, phospho-proteomic profiling identified a significant reduction in the p38 
MAPK levels in vivo (164). In connection to our abovementioned cyclin D1 
downregulation and slight increase in cell cycle arrest after RICTOR inhibition, p38 
has been shown to negatively regulate cell cycle progression by inducing a G1/S 
checkpoint in response to osmotic stress, reactive oxygen species, and cell 
senescence stimuli (136). Specifically, p38 has been connected with reducing the 
levels of cyclin D1 either through an indirect transcriptional repression mechanism 
(165, 166), or through direct phosphorylation of cyclin D1, resulting in ubiquitination 
and proteosomal degradation (135). These data suggest that there could be a link 
between RICTOR and p38α in modulating the cell cycle progression and cellular 
stress response in the NSCLC cell lines tested. Accordingly, accumulating evidence 
has shown that RICTOR/mTORC2 is linked to the regulation of metabolic stress, 
inflammatory response, and energy balance in various contexts (167-170). 
Furthermore, it is interesting to note that since we determined a compensatory 
activation of p-MEK following RICTOR inhibition, it is plausible that this activated MEK 
could bypass ERK and interact with p38α to mediate alternate survival pathways such 
as autophagy. A study by Wang et al. demonstrated that MEK may play a more 
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important role by bypassing ERK and regulating BECLIN-1 expression to induce 
autophagy, emphasizing a non-canonical MEK-ERK signaling pathway (171). In line 
with this assumption, genetic ablation or targeted inhibition of p38α was shown to 
cause cell cycle arrest and autophagic cell death in colorectal cancer cells (172). A 
more detailed mechanistic study assessing various markers of autophagy, 
senescence, proliferation, and/or apoptosis is needed to fully ascertain the 
mechanism by which we see a reduction in colony formation, cell counts, and 
tumorigenicity following RICTOR inhibition in our pre-clinical NSCLC models. 
The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling pathways are critical 
integrators of mechanisms mediating cell survival, proliferation, differentiation, 
metabolism, and invasion/migration in response to extracellular stimuli. Various 
targeted therapies have been developed directed at each of these major oncogenic 
pathways (173, 174). However, it is now clear that monotherapeutic targeting of 
effectors of these pathways result in resistance mechanisms such as re-activation of 
feedback loops and cross-talk mechanisms. Thus, these acquired bypass 
mechanisms are to blame for the lack of therapeutic efficacy and relapse often seen 
in patients, and therefore prompt the use of combinatorial therapeutic strategies. Our 
in vitro and in vivo data suggest that RICTOR blockade results in a compensatory 
activation of the MAPK pathway, specifically in KRAS co-mutational settings. We 
show that in both RICTOR amplified and non-amplified NSCLC cell lines, RICTOR 
knockdown increases p-MEK levels only when the cells harbor KRAS mutations. This 
is important as mutations in KRAS have been identified in 20-30% of lung cancers 
and are known to serve as crucial drivers of this malignancy, leading to poorer 
prognosis and resistance to chemo- and targeted therapies, yet KRAS still remains an 
101 
 
orphan target in NSCLC and other tumors (3, 175). To date, direct targeting of 
aberrant KRAS activation has been unsuccessful despite significant research efforts 
(176). We exploited this resistance mechanism as a therapeutic vulnerability and 
therefore tested a dual pathway inhibition approach by use of a catalytic mTORC1/2 
inhibitor (AZD2014) and allosteric MEK1/2 inhibitor (selumetinib). Our results suggest 
this combination renders a highly synergistic anti-tumor effect in our RICTOR/KRAS-
altered NSCLC cell lines both in vitro and in vivo.  
Combination strategies with other inhibitors targeting both pathways have been 
proposed and reported, but with varying efficacy and in differing genomic subsets. A 
study by Meng et al. found that combining selumetinib with an AKT inhibitor (MK2206) 
had a significant synergistic effect on tumor growth in vitro and in vivo in NSCLC 
(177). However, they found no correlation between mutational status of KRAS, EGFR, 
BRAF, or PI3K to sensitivity to either drug. Moreover, a study reported that activation 
of the PI3K pathway strongly influences sensitivity to MEK inhibition in RAS mutant 
cells, and thus suggest a combination therapy of PI3K and MEK inhibitors for tumors 
with concomitant mutations of KRAS and PIK3CA (178). However, the role of 
RICTOR in PI3K co-mutational settings is yet to be determined.  
Similar to our proposed strategy, a recent in vitro study signified the rationale of 
combined inhibition of MEK and mTOR signaling in KRAS mutant NSCLC (179). They 
assessed a panel of EGFR/ALK wildtype NSCLC cell lines that are either KRAS 
mutant or wildtype, and have shown that inhibition of mTOR is dominantly responsible 
for the majority of growth inhibition in the combination therapy of mTORC1/2 inhibitor 
(AZD2014) with MEK1/2 inhibitor (trametinib), and the combination is more effective in 
KRAS mutant lines. Interestingly, our in vitro data testing selumetinib and AZD2014 in 
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KRAS mutant cells did not define a clear dominant trend between which drug has the 
more potent effect on cell viability, perhaps due to the diverse co-mutational nature of 
the RICTOR cell line panel. This could also be due to the differences in the MEK 
inhibitor used (selumetinib vs. trametinib), which are known to have differing 
mechanisms of action. Additionally, our in vivo data using the H1792 xenograft model 
actually showed that selumetinib had a more enhanced anti-tumor effect as a single 
agent compared to the mTORC1/2 inhibitor AZD2014, suggesting that this particular 
KRAS mutant cell line (KRASG12C) is more sensitive to MEK1/2 inhibition than 
mTORC1/2, despite having amplification of RICTOR present. 
Nevertheless, these reports and others underscore the combinatorial rational of 
dual pathway inhibition presented here. It would be of interest to elucidate, however, 
whether the development of specific pharmacologic targeting of RICTOR would prove 
beneficial in defined patient populations, namely in RICTOR amplified cases, 
exclusive of other major driver mutations. This would prove beneficial considering that 
RICTOR is known to function independently of the mTORC2 complex, regulating 
other effectors involved in tumor progression. However, in the patient cohort that we 
are targeting here, we believe that dual mTORC1/2 inhibitors, such as AZD2014, are 
still warranted further clinical testing in combination with MEK inhibitors, such as 
selumetinib, as this approach prevents the compensatory feedback we described in 
our study, and other mechanisms often seen by single mTORC1 inhibitors known to 
induce hyperactivation of PI3K-AKT (180). Moreover, although previous reports 
suggest limited clinical benefits from mTORC1/2 inhibitors, proper patient selection in 
lung cancer patients is needed to fully exploit this therapeutic option (181). Lastly, 
although combination therapy might be highly effective in cancer patients, there are 
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great limitations in regards to toxicity. In our proposed strategy specifically, the mTOR 
and MAPK signaling pathways regulate important physiological functions in non-
malignant cells, and thus, an extended treatment setting targeting both pathways 
might not be feasible. It is therefore important to assess various dosing strategies 
(e.g. intermittent versus continuous treatment) to fully define the maximal tolerated 
frequency/doses with the lowest toxicity profile. 
In conclusion, our study uncovers defined molecular settings by which we 
believe can impose clinical benefit to KRAS mutant NSCLC by screening for 
concomitant RICTOR alterations that will determine potential benefit from dual 
mTOR/MAPK pathway inhibition. Excitingly, an ongoing clinical trial termed 
“TORCMEK” (NCT02583542) is recruiting patients with advanced cancers, including 
triple-negative breast cancer and NSCLC (KRAS mutant vs. wild-type tumors), to 
assess feasible dose levels and clinical activity of combining AZD2014 in combination 
with selumetinib. Despite that these targeting agents have been utilized in other 
clinical trials as single agents or in combination with alternative drugs, this specific 
combination has not been tested in the clinical setting. On the basis of our studies, it 
would be of interest to identify if any potential responders to this combination 
harbored RICTOR and/or KRAS alterations. 
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Chapter 8 
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The manuscript described below has been submitted for publication and includes the 
data presented in the results section of this dissertation. 
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